<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680303</article-id><article-id pub-id-type="doi">10.3390/v16121863</article-id><article-id pub-id-type="publisher-id">viruses-16-01863</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Hepatitis C Virus&#x02014;Core Antigen: Implications in Diagnostic, Treatment Monitoring and Clinical Outcomes</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0007-5524-4626</contrib-id><name><surname>Le</surname><given-names>Duong Hoang Huy</given-names></name><xref rid="af1-viruses-16-01863" ref-type="aff">1</xref><xref rid="af2-viruses-16-01863" ref-type="aff">2</xref><xref rid="af3-viruses-16-01863" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9482-6353</contrib-id><name><surname>Kanokudom</surname><given-names>Sitthichai</given-names></name><xref rid="af1-viruses-16-01863" ref-type="aff">1</xref><xref rid="af2-viruses-16-01863" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Nguyen</surname><given-names>Ha Minh</given-names></name><xref rid="af3-viruses-16-01863" ref-type="aff">3</xref><xref rid="af4-viruses-16-01863" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9391-663X</contrib-id><name><surname>Yorsaeng</surname><given-names>Ritthideach</given-names></name><xref rid="af1-viruses-16-01863" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3852-9092</contrib-id><name><surname>Honsawek</surname><given-names>Sittisak</given-names></name><xref rid="af2-viruses-16-01863" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Vongpunsawad</surname><given-names>Sompong</given-names></name><xref rid="af1-viruses-16-01863" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2337-6807</contrib-id><name><surname>Poovorawan</surname><given-names>Yong</given-names></name><xref rid="af1-viruses-16-01863" ref-type="aff">1</xref><xref rid="af5-viruses-16-01863" ref-type="aff">5</xref><xref rid="c1-viruses-16-01863" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Feng</surname><given-names>Zongdi</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-16-01863"><label>1</label>Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand; <email>huyldh@pnt.edu.vn</email> (D.H.H.L.); <email>sitthichai.k@chula.ac.th</email> (S.K.); <email>ritthideach.yor@gmail.com</email> (R.Y.); <email>sompong.vo@chula.ac.th</email> (S.V.)</aff><aff id="af2-viruses-16-01863"><label>2</label>Center of Excellence in Osteoarthritis and Musculoskeleton, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok 10330, Thailand; <email>sittisak.h@chula.ac.th</email></aff><aff id="af3-viruses-16-01863"><label>3</label>Medical Biochemistry &#x00026; Molecular Biology Department, Fundamental Sciences and Basic Medical Sciences, Pham Ngoc Thach University of Medicine, Ho Chi Minh City 700000, Vietnam; <email>nguyenminhha@pnt.edu.vn</email></aff><aff id="af4-viruses-16-01863"><label>4</label>Laboratory Department, Nguyen Tri Phuong Hospital, Ho Chi Minh City 700000, Vietnam</aff><aff id="af5-viruses-16-01863"><label>5</label>The Royal Society of Thailand, Sanam Sueapa, Bangkok 10330, Thailand</aff><author-notes><corresp id="c1-viruses-16-01863"><label>*</label>Correspondence: <email>yong.p@chula.ac.th</email></corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>16</volume><issue>12</issue><elocation-id>1863</elocation-id><history><date date-type="received"><day>04</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>26</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>28</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The hepatitis C virus (HCV) infection, a global health concern, can lead to chronic liver disease. The HCV core antigen (HCVcAg), a viral protein essential for replication, offers a cost-effective alternative to HCV RNA testing, particularly in resource-limited settings. This review explores the significance of HCVcAg, a key protein in the hepatitis C virus, examining its structure, function, and role in the viral life cycle. It also evaluates its clinical use in diagnosis and treatment monitoring, comparing its performance to the standard HCV RNA assay using data from PubMed and Google Scholar. HCVcAg assays show high pooled sensitivity (93.5%) and pooled specificity (99.2%) compared to HCV RNA assays, correlating closely (<italic toggle="yes">r</italic> = 0.87) with HCV RNA levels. Hence, HCVcAg testing offers a cost-effective way to diagnose active HCV infections and monitor treatment, especially in resource-limited settings, but its sensitivity can vary and standardization is needed. HCVcAg also predicts liver disease progression and assesses liver damage risk, aiding patient management. It helps to identify patients at risk for fibrosis or carcinoma, making it vital in hepatitis C care. HCVcAg testing can expand access to HCV care, simplify management, and contribute to global elimination strategies, especially in low- and middle-income countries.</p></abstract><kwd-group><kwd>hepatitis C virus</kwd><kwd>HCV core antigen</kwd><kwd>diagnostics</kwd><kwd>HCV treatment</kwd><kwd>monitoring</kwd><kwd>resource-limited settings</kwd><kwd>global elimination strategies</kwd></kwd-group><funding-group><award-group><funding-source>Chulalongkorn University</funding-source></award-group><award-group><funding-source>MK restaurant Group Aunt Thongkum Foundation</funding-source></award-group><award-group><funding-source>BJC Big C Foundation</funding-source></award-group><award-group><funding-source>Center of Excellence in Clinical Virology</funding-source></award-group><award-group><funding-source>Chulalongkorn University</funding-source></award-group><award-group><funding-source>King Chulalongkorn Memorial Hospital</funding-source></award-group><funding-statement>This study was supported by the &#x0201c;Graduate Scholarship Program for ASEAN or Non-ASEAN countries&#x0201d; by Chulalongkorn University, the MK restaurant Group Aunt Thongkum Foundation, the BJC Big C Foundation, the Center of Excellence in Clinical Virology, Chulalongkorn University, and the King Chulalongkorn Memorial Hospital.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-16-01863"><title>1. Introduction</title><sec id="sec1dot1-viruses-16-01863"><title>1.1. A Brief Overview of HCV</title><p>The hepatitis C virus (HCV) is a blood-borne pathogen that primarily infects the liver. Transmission occurs through exposure to infected blood, primarily via contaminated needles, unscreened blood transfusions, and high-risk sexual practices. Acute HCV infection often goes unnoticed, due to mild or absent symptoms [<xref rid="B1-viruses-16-01863" ref-type="bibr">1</xref>]. However, chronic infection can lead to severe liver complications, including cirrhosis, liver failure, and hepatocellular carcinoma (HCC). As a consequence, HCV infection is a significant global health concern, contributing to an estimated 290,000 deaths annually [<xref rid="B2-viruses-16-01863" ref-type="bibr">2</xref>]. Previously considered incurable, advancements in direct-acting antivirals (DAAs) therapies have revolutionized HCV treatment, achieving cure rates exceeding 95% in many cases [<xref rid="B3-viruses-16-01863" ref-type="bibr">3</xref>]. Achieving the World Health Organization (WHO) policy for hepatitis C elimination goals by 2030, however, requires a multifaceted public health strategy that includes prevention, screening, diagnostic, and treatment programs tailored to the needs of key affected populations.</p></sec><sec id="sec1dot2-viruses-16-01863"><title>1.2. Structure of HCV Virion</title><p>The HCV virion is a small, enveloped virus with a positive-sense, single-stranded RNA (ssRNA) genome. The HCV capsid is entirely formed by the core protein, which adopts an icosahedral shape. The inner surface of the capsid binds the ssRNA genetic material, while the outer surface interacts with the viral membrane or envelope. The envelope consists of a lipid bilayer and two glycoproteins, E1 and E2 (<xref rid="viruses-16-01863-f001" ref-type="fig">Figure 1</xref>). The E1 and E2 proteins are responsible for viral attachment and entry into host cells [<xref rid="B4-viruses-16-01863" ref-type="bibr">4</xref>].</p></sec><sec id="sec1dot3-viruses-16-01863"><title>1.3. HCV Genome</title><p>The HCV genome consists of a single-stranded, positive-sense RNA molecule approximately 9600 nucleotides long. This genome encodes a single open reading frame (ORF) of 3010 amino acids, flanked by 5&#x02032; and 3&#x02032; untranslated regions (UTRs) essential for viral replication and translation. The 5&#x02032; NTR contains an internal ribosome entry site (IRES). The translation of the HCV genome begins at the 5&#x02032; UTR internal ribosome entry site (IRES), producing a single polyprotein. Cellular proteases cleave this polyprotein to generate structural proteins (core, E1, and E2) that form viral particles. Viral proteases further process the polyprotein to produce non-structural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B) [<xref rid="B5-viruses-16-01863" ref-type="bibr">5</xref>].</p></sec><sec id="sec1dot4-viruses-16-01863"><title>1.4. Variability of HCV</title><p>HCV exhibits significant genetic diversity due to the error-prone nature of its RNA-dependent RNA polymerase, which lacks 5&#x02032; to 3&#x02032; exonuclease activity for proofreading. This results in frequent nucleotide substitutions and contributes to the high degree of genetic variability observed in HCV populations. The mean frequency of nucleotide mutations varies from 1.4 &#x000d7; 10<sup>3</sup> to 1.9 &#x000d7; 10<sup>3</sup> substitutions per nucleotide and per year [<xref rid="B5-viruses-16-01863" ref-type="bibr">5</xref>,<xref rid="B6-viruses-16-01863" ref-type="bibr">6</xref>]. Rapid mutation in HCV creates a diverse population of viruses, known as quasispecies. These quasispecies are classified by differences in specific parts of the virus&#x02019;s envelope protein and nonstructural 5A protein [<xref rid="B7-viruses-16-01863" ref-type="bibr">7</xref>].</p><p>HCV genome conservation varies across different regions. Regions encoding essential functions (e.g., translation, replication) or exhibiting structural constraints (e.g., 5&#x02032; and 3&#x02032; UTRs) show high conservation. The 5&#x02032; UTR demonstrates the highest conservation (&#x0003e;90% sequence identity) even among distantly related strains. The capsid-encoding region also exhibits considerable conservation (approximately 80% identity). Conversely, the envelope glycoprotein-encoding region displays significant variability, particularly within the hypervariable regions (HVR1 and HVR2) of E2, where inter-strain sequence identity can be as low as 50%. This variability likely contributes to immune evasion and viral persistence. Structural studies suggest that mechanisms may include point mutations within the epitope, allosteric modulation of the epitope by distal mutations, and glycan shifting on envelope glycoproteins. Consequently, the polypeptides encoded by these hypervariable regions are highly tolerant of amino acid substitutions [<xref rid="B8-viruses-16-01863" ref-type="bibr">8</xref>].</p><p>The classification of HCV is based on the topology of phylogenetic trees derived from viral variant relationships. Until recently, HCV was divided into seven main types based on significant genetic differences (&#x0003e;30% at the nucleotide level) [<xref rid="B9-viruses-16-01863" ref-type="bibr">9</xref>,<xref rid="B10-viruses-16-01863" ref-type="bibr">10</xref>]. A new type, HCV genotype 8, was recently discovered in India in 2018 [<xref rid="B11-viruses-16-01863" ref-type="bibr">11</xref>]. This new type is genetically distinct from the previously known types. Genotypes are further divided into subtypes. Based on the consensus criteria [<xref rid="B12-viruses-16-01863" ref-type="bibr">12</xref>], to be confirmed as a new subtype, a virus must have a unique genetic sequence that is different from other known subtypes by at least 15% and sequence information from at least two other isolates in the core/E1 (&#x0003e;90% of the sequence corresponding to positions 869 to 1292 of the H77 reference sequence) and the NS5B region (&#x0003e;90% of positions 8276 to 8615) of the virus&#x02019;s genome [<xref rid="B12-viruses-16-01863" ref-type="bibr">12</xref>]. To date, over 90 confirmed HCV subtypes have been described [<xref rid="B10-viruses-16-01863" ref-type="bibr">10</xref>,<xref rid="B13-viruses-16-01863" ref-type="bibr">13</xref>]. The virus genotype is indicated by an Arabic number (from 1 to 8), associated with a lower-case letter to indicate the subtype. The phylogenetic tree depicted in <xref rid="viruses-16-01863-f002" ref-type="fig">Figure 2</xref> illustrates the evolutionary relationships among all known, assigned, provisionally assigned, or unassigned subtypes of the eight HCV genotypes, based on complete genome sequences retrieved from the NCBI Genbank.</p></sec><sec id="sec1dot5-viruses-16-01863"><title>1.5. HCV Genotypes</title><p>Phylogenetic analysis permitted the classification of HCV into 8 major genotypes and 86 subtypes [<xref rid="B10-viruses-16-01863" ref-type="bibr">10</xref>]. The global distribution of HCV genotypes and subtypes also varies by geographic region, ethnicity, and risk groups. Genotypes 1 and 3 are the most prevalent, accounting for more than 30% of all infections. Genotypes 2, 4, 5, and 6 account for less than 10% of infections, respectively. Genotype 7 has been found in a few people from Central Africa [<xref rid="B9-viruses-16-01863" ref-type="bibr">9</xref>,<xref rid="B14-viruses-16-01863" ref-type="bibr">14</xref>].</p><p>The HCV genotype distribution varies geographically. Genotype 1 predominates in Europe and North America, followed by genotypes 2 and 3. Genotype 2 is most prevalent in Central Africa, while genotype 3 is common in India, Pakistan, Thailand, other Asian countries, and Northern Europe. Genotypes 4 and 5, likely disseminated through migration and intravenous drug use, are increasing in prevalence. Genotype 4 is primarily found in Central Africa and the Middle East, whereas genotype 5 is more frequently found in Southern Africa. The HCV genotype 6 has a high variation, classified as more than five subtypes. They are highly prevalent in East and Southeast Asia and are mostly found in Laos and Vietnam [<xref rid="B5-viruses-16-01863" ref-type="bibr">5</xref>], and northern and northeast Thailand [<xref rid="B15-viruses-16-01863" ref-type="bibr">15</xref>].</p></sec></sec><sec id="sec2-viruses-16-01863"><title>2. HCV Core Antigen (HCVcAg)</title><sec id="sec2dot1-viruses-16-01863"><title>2.1. Definition and Structure</title><p>The HCV core protein, which is released from polyproteins by a signal peptidase (SP), is a 23 kDa precursor protein containing 191 amino acids [<xref rid="B16-viruses-16-01863" ref-type="bibr">16</xref>], organized into three distinct regions D1, D2, and D3. This precursor core protein is subsequently processed by a signal peptide peptidase (SPP), producing a mature, two-domain (D1 and D2) protein of approximately 177 amino acids.</p><p>The first region, composed of 117 amino acids, is rich in basic residues and contains short hydrophobic segments, binding to the viral RNA. The underlying mechanism is that hydrophobic segments, due to their inherent properties, tend to exclude water molecules. While viral RNA possesses negatively charged phosphate groups, it also contains hydrophobic bases (adenine, guanine, cytosine, and uracil). These hydrophobic bases can engage in favorable interactions with the hydrophobic amino acids present in the core antigen, ultimately resulting in binding. The second region is more hydrophobic and anchors the core protein to lipid droplets (LDs), intracellular structures that store lipids. The final region, containing the signal sequence for another viral protein, is located at the protein&#x02019;s end. Based on the charge distribution, the D1 domain can be further subdivided into three basic clusters: BD1 (basic domain 1), BD2 (basic domain 2) and BD3 (basic domain 3). The D2 domain contains two amphipathic &#x003b1;-helices, Helix I (HI) and Helix II (HII), separated by a hydrophobic loop (HL) [<xref rid="B17-viruses-16-01863" ref-type="bibr">17</xref>] (<xref rid="viruses-16-01863-f003" ref-type="fig">Figure 3</xref>). Mature core proteins typically form clusters at the endoplasmic reticulum (ER) membrane and can assemble into virus-like particles [<xref rid="B18-viruses-16-01863" ref-type="bibr">18</xref>]. The D3 region is a short peptide composed of around 15 amino acids, playing a crucial role in signal transduction [<xref rid="B19-viruses-16-01863" ref-type="bibr">19</xref>]. Beyond its structural role, the core protein interacts with viral RNA during capsid formation and regulates RNA translation [<xref rid="B19-viruses-16-01863" ref-type="bibr">19</xref>]. Additionally, it is implicated in various cellular processes, including apoptosis, lipid metabolism, and liver cancer development. Notably, the core protein can alter the distribution of LDs within cells, which is linked to virus assembly and fat accumulation in the liver. Disrupting the core protein&#x02019;s interaction with LDs hinders virus production. Furthermore, the core protein influences intracellular calcium levels. Thus, this protein is not only essential for viral structure but also plays a crucial role in regulating cellular functions and contributing to the virus&#x02019;s life cycle [<xref rid="B20-viruses-16-01863" ref-type="bibr">20</xref>].</p><p>The current understanding suggests that HCV particles are produced near LDs, where they acquire an envelope in the ER [<xref rid="B17-viruses-16-01863" ref-type="bibr">17</xref>] before being released from the cell via the secretory pathway, a process associated with very low-density lipoproteins (VLDLs) production. Research has consistently shown a strong connection between the HCV assembly process and LDs (<xref rid="viruses-16-01863-f003" ref-type="fig">Figure 3</xref>). Even before the development of the HCV cell culture system (HCVcc), studies revealed that the HCV core protein is located on the surface of LDs.</p><p>The HCV infection of hepatocytes is a multi-stage process involving interactions with host cell surface proteins, including CD81, SRB1, Claudin 1, and Occludin. Upon entry via endocytosis and fusion with the endosomal membrane, the viral RNA is released into the cytoplasm. Host cell machinery translates this RNA into a polyprotein, from which HCV structural proteins (core, E1, and E2) are liberated from the polyprotein by host proteases. In contrast, the liberation of the six nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) relies on a combination of host and viral proteases. These nonstructural proteins possess enzymatic activities essential for the HCV life cycle. Notably, NS2 and NS3 function as viral proteases involved in polyprotein processing, with the NS3/NS4A complex specifically mediating the release of NS5A and NS5B. The replication of the viral RNA genome is primarily mediated by the NS5B polymerase and NS3 helicase. The assembly of progeny virions involves the coordinated interaction of the viral core protein with LDs, facilitating the encapsulation of newly replicated RNA genomes by structural proteins derived from the polyprotein. In addition to its crucial role as a key protein in the replication process, NS5A is believed to be essential for the assembly and release of viral particles. Therefore, NS5A represents a critical target for direct-acting antiviral drugs. Finally, mature virions are released from the hepatocyte, perpetuating the viral life cycle [<xref rid="B17-viruses-16-01863" ref-type="bibr">17</xref>,<xref rid="B21-viruses-16-01863" ref-type="bibr">21</xref>] (<xref rid="viruses-16-01863-f004" ref-type="fig">Figure 4</xref>).</p><p>The viral RNA is packaged into newly formed core oligomers as a result of the interaction between the core and NS5A on or near the LDs. This process is likely to trigger capsid assembly. P7 recruits the core assembly intermediate to the ER membrane, which is essential for the completion of capsid assembly and the initiation of budding. NS2 brings replication and assembly sites into proximity through its interaction with glycoproteins E1 and E2, and NS3/4A (<xref rid="viruses-16-01863-f004" ref-type="fig">Figure 4</xref>). Altering specific regions of the core protein, such as the signal peptide peptidase cleavage site or the D2 domain, impedes the core protein&#x02019;s localization to LDs and ultimately inhibits the virus&#x02019;s ability to become infectious [<xref rid="B22-viruses-16-01863" ref-type="bibr">22</xref>]. Further investigations using the HCVcc system corroborated that LDs are essential for producing infectious HCV particles and highlighted the crucial roles of the core and NS5A proteins in this process. Both the core and NS5A proteins must be directed to LDs for successful virus production [<xref rid="B23-viruses-16-01863" ref-type="bibr">23</xref>].</p></sec><sec id="sec2dot2-viruses-16-01863"><title>2.2. The Role of HCVcAg in Viral Replication</title><p>A major component of the viral particle is the core protein, which interacts with genomic RNA to form the nucleocapsid. After being synthesized on ER membranes and cleaved by the signal peptide peptidase, the core protein forms pairs with itself (homodimerizes) and is then transported to LDs in the cell. The interaction between the HCV core protein and LDs is believed to be crucial for gathering other viral components necessary for building new virus particles. The core protein has a section at its end (C-terminal domain) with two special structures (amphipathic helices) that bind to LDs. As more core proteins accumulate around LDs, the distribution of LDs within the cell changes significantly. Normally, LDs are spread throughout the cell in uninfected cells, but they gather near the cell nucleus when infected with HCV. Importantly, changes to the core protein that prevent it from binding to LDs strongly hinder the virus from forming new particles. Interestingly, when observed live, the core protein quickly moves to LDs and then gradually forms moving clusters (puncta) that travel along microtubules and are likely new virus particles in the process of being released from the cell [<xref rid="B17-viruses-16-01863" ref-type="bibr">17</xref>].</p><p>It is important to note that the amount of core protein that accumulates on LDs is inversely related to how efficiently the virus produces infectious particles [<xref rid="B24-viruses-16-01863" ref-type="bibr">24</xref>]. This might be because the core protein only stays on LDs temporarily before moving to other parts of the cell, where new viruses are assembled. The relationship between the core protein and LDs can also be influenced by proteins from the host cell. For example, an enzyme called diacylglycerol acyltransferase-1 (DGAT1) involved in forming LDs has been shown to interact with the core protein, helping it bind to LDs and allowing the virus to multiply [<xref rid="B25-viruses-16-01863" ref-type="bibr">25</xref>]. The movement of the core protein to LDs also requires a cellular enzyme called phospholipase A2 (PLA2G4) that is controlled by another cellular system (MAPK) and its product, arachidonic acid [<xref rid="B26-viruses-16-01863" ref-type="bibr">26</xref>]. Surprisingly, another cellular protein called I&#x003ba;B kinase-&#x003b1; (IKK-&#x003b1;) has also been found to be essential for HCV assembly. It has been reported that HCV RNA activates IKK-&#x003b1;, which moves into the cell nucleus and triggers a chain of events involving other cellular proteins (CBP/p300) and regulatory molecules (SREBPs) [<xref rid="B27-viruses-16-01863" ref-type="bibr">27</xref>]. This process leads to the increased production of fat-related genes and promotes the formation of LDs with attached core proteins, making it easier for the virus to assemble [<xref rid="B17-viruses-16-01863" ref-type="bibr">17</xref>].</p><p>The interaction between the core protein and LDs is dynamic, and the core protein needs to be removed from the surface of LDs to move to the place where new viruses bud off. A cellular protein called AP2M1 has been found to interact with a specific sequence (YXX&#x000d8; motif) on the HCV core protein, which is important for removing the core protein from LDs and leading to virus assembly. However, this finding is difficult to explain because this specific sequence on the core protein is not easily accessible [<xref rid="B28-viruses-16-01863" ref-type="bibr">28</xref>,<xref rid="B29-viruses-16-01863" ref-type="bibr">29</xref>].</p></sec><sec id="sec2dot3-viruses-16-01863"><title>2.3. Core Antigen as a Tool for Diagnostic Testing</title><p>HCVcAg is a versatile biomarker detectable by a wide array of immunoassay techniques [<xref rid="B30-viruses-16-01863" ref-type="bibr">30</xref>,<xref rid="B31-viruses-16-01863" ref-type="bibr">31</xref>]. When nucleic acid testing (NAT) for hepatitis C is unavailable due to resource constraints, the WHO recommends using an HCVcAg test to detect active infection [<xref rid="B32-viruses-16-01863" ref-type="bibr">32</xref>]. These include traditional methods such as enzyme immunoassay (EIA), chemiluminescence immunoassay (CIA), and radioimmunoassay (RIA), as well as more advanced approaches like recombinant immunoblot assay (RIBA), electrochemical immunosensors (EI), and nanotechnology-based assays [<xref rid="B33-viruses-16-01863" ref-type="bibr">33</xref>]. Additionally, rapid point-of-care (POC) testing is enabled through lateral flow assays (LFA), demonstrating the breadth of methodologies available for detecting HCVcAg. In particular, in a study by Wang et al., a highly specific aptamer was used to establish a sensitive method for the detection of the HCV core antigen. The analytical performance of this method was evaluated, revealing impressive detection limits of 10 pg/mL<sup>&#x02212;1</sup> when analyzed with a scanner and 100 pg/mL<sup>&#x02212;1</sup> when assessed visually [<xref rid="B34-viruses-16-01863" ref-type="bibr">34</xref>]. While each method offers distinct advantages, the EIA and CIA techniques are commonly applied by diagnostic companies in their commercial products and are widely used in clinical settings.</p><p>The WHO&#x02019;s 2023 updated guidelines on &#x0201c;New recommendation on hepatitis C virus testing and treatment for people at ongoing risk of infection&#x0201d; acknowledge the role of HCVcAg testing [<xref rid="B32-viruses-16-01863" ref-type="bibr">32</xref>]. This assay is recognized as one of four options for confirming active HCV infection following a reactive anti-HCV antibody test. According to the 2023 WHO guidelines (<xref rid="viruses-16-01863-f005" ref-type="fig">Figure 5</xref>), the diagnosis of HCV infection before treatment initiation involves a two-step process [<xref rid="B32-viruses-16-01863" ref-type="bibr">32</xref>]. The first step, screening, can be performed through rapid diagnostic tests (RDTs) without the need for laboratory infrastructure. However, for confirmatory testing, three options among the four require centralized laboratory assays, including HCVcAg testing, except for POC HCV RNA. It is noteworthy that while the WHO, the Infectious Diseases Society of America (IDSA), and the American Association for the Study of Liver Diseases (AASLD) guidelines do not mention the use of HCVcAg for monitoring sustained virological response (SVR) post-treatment, the European Association for the Study of the Liver (EASL) guidelines acknowledge its role in monitoring after direct-acting antiviral therapy [<xref rid="B32-viruses-16-01863" ref-type="bibr">32</xref>,<xref rid="B35-viruses-16-01863" ref-type="bibr">35</xref>,<xref rid="B36-viruses-16-01863" ref-type="bibr">36</xref>]. For resource-limited settings, a practical approach is recommended: initial screening using serological tests followed by the confirmation of viral infection with HCVcAg. Furthermore, post-treatment monitoring with HCVcAg could also be considered in these settings. The sensitivity, specificity, and correlation of HCVcAg with the gold standard laboratory-based HCV RNA assay will be discussed in detail in subsequent sections.</p></sec><sec id="sec2dot4-viruses-16-01863"><title>2.4. Comparison of HCVcAg with Other HCV Markers (Anti-HCV, HCV RNA)</title><p>Current guidelines from leading global organizations, including the European Association for the Study of the Liver, the Infectious Diseases Society of America, the American Association for the Study of Liver Diseases and the WHO, consistently affirm that HCV RNA testing is the gold standard for diagnosing and monitoring hepatitis C infection [<xref rid="B32-viruses-16-01863" ref-type="bibr">32</xref>,<xref rid="B35-viruses-16-01863" ref-type="bibr">35</xref>,<xref rid="B36-viruses-16-01863" ref-type="bibr">36</xref>,<xref rid="B37-viruses-16-01863" ref-type="bibr">37</xref>]. Specifically, the WHO strongly recommends the use of qualitative or quantitative HCV RNA laboratory-based assays. This recommendation stems from the test&#x02019;s ability to directly detect viral genetic material, thus reflecting viral replication and providing a definitive assessment of an active infection. However, widespread implementation of HCV RNA testing can be challenging due to its technical demands. These include the need for real-time PCR systems, highly trained personnel, and significant financial investment. Consequently, HCVcAg testing, which directly detects viral antigens, has emerged as a recommended alternative for confirming HCV infection. The expression of HCVcAg is highly consistent with that of HCV RNA, but compared with HCV RNA, the detection of HCVcAg is easy to operate, time-saving, and low cost. HCVcAg can be detected within 12~15 days after infection, and the window period can be shortened by 5~7 weeks. In particular, HCVcAg can be detected 1.5 months (38 to 50 days) earlier than anti-HCV and 1 to 2 days after the appearance of HCV RNA in blood samples of newly infected individuals [<xref rid="B38-viruses-16-01863" ref-type="bibr">38</xref>] (<xref rid="viruses-16-01863-t001" ref-type="table">Table 1</xref>). HCVcAg is a serological indicator of virus replication, which can distinguish between previous infection of HCV or current infection. HCVcAg detection is particularly advantageous for immunocompromised individuals, hemodialysis patients, and organ transplant recipients (detail research in <xref rid="viruses-16-01863-t002" ref-type="table">Table 2</xref>). This stems from the fact that HCV core antigen detection is independent of the host&#x02019;s immune response, unlike antibody-based assays. HCVcAg can also be used to monitor antiviral efficacy and predict SVR [<xref rid="B39-viruses-16-01863" ref-type="bibr">39</xref>]. <xref rid="viruses-16-01863-t001" ref-type="table">Table 1</xref> presents a comparative analysis of three serological markers (anti-HCV, HCVcAg, and HCV RNA) recommended within the WHO diagnostic algorithm. This analysis encompasses the key characteristics, advantages, and limitations of each marker.</p></sec></sec><sec id="sec3-viruses-16-01863"><title>3. Clinical Significance of HCVcAg for Diagnosis and Monitor Treatment</title><p>We have reviewed and synthesized data from approximately 80 studies to elucidate the value of the HCVcAg test. Our focus has been primarily on the test&#x02019;s utility in both HCV diagnosis and treatment monitoring, particularly in the era of direct-acting antiviral agents. While HCV RNA testing remains the gold standard for detecting HCV infection, the HCVcAg test offers a faster and more cost-effective alternative. These findings also collectively support the conclusion that the HCVcAg test provides a reliable and accessible approach for HCV diagnosis, especially in resource-limited settings where RNA-based assays may be less available. The subsequent sections will delve into the significance of HCVcAg testing in diagnostic, treatment monitoring, and predictive applications.</p><sec id="sec3dot1-viruses-16-01863"><title>3.1. HCVcAg as a Diagnostic Marker for Active Infection</title><p>HCVcAg presents multiple advantages for diagnosing active infections. Its earlier appearance compared to HCV antibodies, specific expression during active infection, and ability to differentiate between current and past infections enhance its diagnostic utility. Furthermore, HCVcAg detection remains unaffected by immunosuppression. While exhibiting a strong correlation with HCV RNA levels, HCVcAg assays offer advantages in terms of ease of use, reduced processing time, and lower cost. These characteristics position HCVcAg as a potential alternative to HCV RNA for diagnosing active infection. Combining HCVcAg and antibody serology can improve early detection, accurately stage HCV infection, and monitor the antiviral treatment response, ultimately contributing to improved hepatitis C management.</p><p><xref rid="viruses-16-01863-t002" ref-type="table">Table 2</xref> presents a meta-analysis of 53 studies evaluating the diagnostic performance of HCVcAg testing compared to the gold standard RT-PCR. The HCVcAg assay exhibited excellent sensitivity and specificity. The pooled sensitivity and specificity from studies of HCVcAg were calculated by selecting the overall population sensitivity and specificity in the study and using the Architect HCVcAg assay. The pooled sensitivity was 93.5% (95% CI: 91.8&#x02013;95.3%), while the pooled specificity was 99.2% (95% CI: 98.7&#x02013;99.6%). Furthermore, a strong correlation was observed between HCVcAg and HCV RNA levels, with a mean correlation coefficient (<italic toggle="yes">r</italic>) of 0.87 (95% CI: 0.84&#x02013;0.90). <xref rid="viruses-16-01863-f006" ref-type="fig">Figure 6</xref> illustrates that approximately 80% of the studies reported a correlation coefficient exceeding 0.8, indicating a strong association between HCVcAg and HCV RNA. Only one study demonstrated a correlation coefficient below 0.6 [<xref rid="B40-viruses-16-01863" ref-type="bibr">40</xref>].</p><p>Further analysis shows that previous studies predominantly used serum or plasma samples. However, there was no statistically significant difference in the correlation between these two sample types [<xref rid="B41-viruses-16-01863" ref-type="bibr">41</xref>,<xref rid="B42-viruses-16-01863" ref-type="bibr">42</xref>,<xref rid="B43-viruses-16-01863" ref-type="bibr">43</xref>,<xref rid="B44-viruses-16-01863" ref-type="bibr">44</xref>,<xref rid="B45-viruses-16-01863" ref-type="bibr">45</xref>]. The impact of specific populations on the diagnostic value of HCVcAg assays has also been investigated in several studies. Heidrich et al. investigated the correlation between HCVcAg and HCV RNA in liver and kidney transplant recipients. Their findings demonstrated a strong correlation in both groups, with correlation coefficients of 0.85 and 0.969, respectively [<xref rid="B46-viruses-16-01863" ref-type="bibr">46</xref>]. Studies in patients undergoing hemodialysis also showed a high degree of correlation. Wong (Taiwan) and Chuaypen (Thailand) reported correlation coefficients of 0.833 and 0.956, respectively [<xref rid="B44-viruses-16-01863" ref-type="bibr">44</xref>,<xref rid="B47-viruses-16-01863" ref-type="bibr">47</xref>], in this population. In patients co-infected with HBV and/or HIV, the correlation remained strong compared to the general population with HCV mono-infection [<xref rid="B48-viruses-16-01863" ref-type="bibr">48</xref>,<xref rid="B49-viruses-16-01863" ref-type="bibr">49</xref>].</p><p>On the other hand, this review also examined the use of dried blood spots (DBS) [<xref rid="B50-viruses-16-01863" ref-type="bibr">50</xref>,<xref rid="B51-viruses-16-01863" ref-type="bibr">51</xref>], which demonstrated a high degree of concordance with serum and plasma samples, although the sensitivity was lower compared to when using the latter two sample types. Furthermore, the impact of storage time on test performance was investigated by Troyano-Hern&#x000e1;ez et al. who found that, within a reasonable timeframe, the HCVcAg test quality remained sufficient for diagnostic purposes [<xref rid="B52-viruses-16-01863" ref-type="bibr">52</xref>]. However, current guidelines from the EASL do not recommend the use of whole blood or dried blood spots samples for the quantification of HCVcAg in clinical practice [<xref rid="B36-viruses-16-01863" ref-type="bibr">36</xref>].</p><p>Based on these findings and previous analyses, it can be concluded that HCVcAg testing can effectively replace HCV RNA testing, offering exceptionally high sensitivity and specificity. Moreover, current guidelines (WHO 2023) support this notion, recommending a rapid diagnostic test or laboratory-based immunoassay as the initial step, followed by lab-based HCV RNA (qualitative or quantitative), HCVcAg assays, or POC HCV RNA assays to confirm active infection [<xref rid="B32-viruses-16-01863" ref-type="bibr">32</xref>,<xref rid="B36-viruses-16-01863" ref-type="bibr">36</xref>].</p><table-wrap position="anchor" id="viruses-16-01863-t002"><object-id pub-id-type="pii">viruses-16-01863-t002_Table 2</object-id><label>Table 2</label><caption><p>A comprehensive review of studies on the value of HCVcAg in diagnosis from 2010 to the present.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No.</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Author (Year) [Ref.]</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Country<break/>(Continent)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sample Size</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HCV Genotype</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Medical History</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sample Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HCVcAg Reagent<break/>(LOD cut off)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HCV RNA Viral Load<break/>(IU/mL)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sensitivity<break/>(95%CI)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Specificity<break/>(95%CI)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Correlation (<italic toggle="yes">p</italic>-Value)</th></tr></thead><tbody><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Miedouge et al. (2010) [<xref rid="B53-viruses-16-01863" ref-type="bibr">53</xref>]</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">France<break/>(Europe)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2913</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1, 2, 3, 4, 5, 6</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SR</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;2000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53.85%<break/>(25&#x02013;81%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99%<break/>(99&#x02013;100%)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.9041<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2001&#x02013;6000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">88.24%<break/>(64&#x02013;99%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99%<break/>(99&#x02013;100%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;6000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99%<break/>(99&#x02013;100%)</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Park et al. (2010) [<xref rid="B54-viruses-16-01863" ref-type="bibr">54</xref>]</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Korea<break/>(Asia)</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">282</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SR</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9521<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9513<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9429<break/>(<italic toggle="yes">p</italic> = 0.0048)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90.2%<break/>(85&#x02013;94%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(97&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9464<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">3</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Ergunay et al. (2011) [<xref rid="B55-viruses-16-01863" ref-type="bibr">55</xref>]</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Turkey<break/>(Europe)</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">272</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1, 2, 3</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SR</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;10<sup>3</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.066<break/>(<italic toggle="yes">p</italic> = 0.561)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>3</sup>&#x02013;10<sup>4</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.595<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>4</sup>&#x02013;10<sup>5</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.404 <break/>(<italic toggle="yes">p</italic> = 0.002)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>5</sup>&#x02013;10<sup>6</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.724<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02265;10<sup>6</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.897 <break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75.8%<break/>(66&#x02013;78%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95.1%<break/>(84&#x02013;99%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.915<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">4</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Kesli et al. (2011) [<xref rid="B56-viruses-16-01863" ref-type="bibr">56</xref>]</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Turkey<break/>(Europe)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">212</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SR</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;10<sup>5</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02265;10<sup>5</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.907<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.3%<break/>(92&#x02013;99%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(93&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.864<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">5</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Kuo et al. (2012) [<xref rid="B57-viruses-16-01863" ref-type="bibr">57</xref>]</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Taiwan<break/>(Asia)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">405</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.8 %<break/>(93&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.1%<break/>(95&#x02013;99%)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.97<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG<break/>(10fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94.6%<break/>(90&#x02013;98%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.7%<break/>(97&#x02013;99%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alados-Arboledas et al.<break/>(2013) [<xref rid="B58-viruses-16-01863" ref-type="bibr">58</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spain<break/>(Europe)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">127</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95%<break/>(89&#x02013;99%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95%<break/>(83&#x02013;99%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hadziyannis et al. (2013) [<xref rid="B59-viruses-16-01863" ref-type="bibr">59</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Greece<break/>(Europe)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">105</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1, 2, 3, 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98%<break/>(92&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(79&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.89<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Buket et al. (2014) [<xref rid="B60-viruses-16-01863" ref-type="bibr">60</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Turkey<break/>(Europe)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">115</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86.5%<break/>(78&#x02013;93%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(82&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">9</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Chevaliez (2014) [<xref rid="B61-viruses-16-01863" ref-type="bibr">61</xref>]</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">France<break/>(Europe)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">188</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SR</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.82<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.75<break/>(<italic toggle="yes">p</italic> = 0.0009)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.92<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.89<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">514</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1, 2, 3, 4, 5, 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98%<break/>(96&#x02013;99%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(98&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.89<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Florea et al. (2014) [<xref rid="B62-viruses-16-01863" ref-type="bibr">62</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Romania<break/>(Europe)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">76</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.5%<break/>(97&#x02013;99%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(81&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.98<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">11</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Garbuglia et al. (2014) [<xref rid="B63-viruses-16-01863" ref-type="bibr">63</xref>]</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Italy<break/>(Europe)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">117</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">100%HIV<break/>3.8%HBV</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">PM</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.82</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.74</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.84</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">249</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1, 2, 3, 4, others</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92%<break/>(78&#x02013;98%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(80&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.7420 <break/>(<italic toggle="yes">p</italic> = 0.05)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">106</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1, 2, 3, 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92%<break/>(78&#x02013;98%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100<break/>(80&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.881<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">12</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Heidrich et al. (2014) [<xref rid="B46-viruses-16-01863" ref-type="bibr">46</xref>]</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Germany<break/>(Europe)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">789</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1, 2, 3, others</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">w/o Tx</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SR</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91%<break/>(88&#x02013;93%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99%<break/>(96&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.736<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">185</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LTx</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98%<break/>(94&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(90&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.850<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NTx</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96%<break/>(78&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(77&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.969<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">424</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;10<sup>5</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001<break/>(<italic toggle="yes">p</italic> = 0.978)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">587</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02265;10<sup>5</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.805<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1011</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92.57%<break/>(90&#x02013;94%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.94%<break/>(97&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.803<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kadkhoda et al. (2014) [<xref rid="B64-viruses-16-01863" ref-type="bibr">64</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Canada<break/>(America)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">154</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1, 2, 3, 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3% HIV<break/>0% HBV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87%<break/>(78&#x02013;93%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97%<break/>(89&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reyes-Mendez et al.<break/>(2014) [<xref rid="B65-viruses-16-01863" ref-type="bibr">65</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mexico<break/>(America)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">211</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91.7%<break/>(78&#x02013;98%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(80&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.97<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Van Helden et al. (2014) [<xref rid="B66-viruses-16-01863" ref-type="bibr">66</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Germany<break/>(Europe)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3558</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1, 2, 3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.4% HIV<break/>6.6% HBV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.0%<break/>(98&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.2%<break/>(99&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.73<break/>(<italic toggle="yes">p</italic> = 0.0003)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kamal et al. (2015) [<xref rid="B67-viruses-16-01863" ref-type="bibr">67</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Egypt<break/>(Africa)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">410</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0% HIV<break/>2.2% HBV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.53%<break/>(99&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.81%<break/>(93&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.944<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Demircili et al. (2016) [<xref rid="B68-viruses-16-01863" ref-type="bibr">68</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Turkey<break/>(Europe)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">189</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1, 2, 3, 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.2%<break/>(89&#x02013;99%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(97&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.874<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.01)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Medici et al. (2016) [<xref rid="B41-viruses-16-01863" ref-type="bibr">41</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Italy<break/>(Europe)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">188</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PM<break/>SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98%<break/>(92&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99%<break/>(94&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.82<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alonso et al. (2017) [<xref rid="B69-viruses-16-01863" ref-type="bibr">69</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spain<break/>(Europe)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1, 2, 3, 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35.7% HIV<break/>28.6%<break/>HBV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.2%<break/>(66&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(77&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.871<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">19</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">&#x000c7;etiner et al. (2017) [<xref rid="B70-viruses-16-01863" ref-type="bibr">70</xref>]</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Turkey<break/>(Europe)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1, 2, 3, 4</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SR</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;10<sup>3</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.294<break/>(<italic toggle="yes">p</italic> = 0.145)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>3</sup>&#x02013;10<sup>5</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.815<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>5</sup>&#x02013;10<sup>6</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.785<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02265;10<sup>6</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.755<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">132</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93.75%<break/>(88&#x02013;97%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(83&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.966<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">20</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Duchesne et al. (2017) [<xref rid="B48-viruses-16-01863" ref-type="bibr">48</xref>]</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Cameroon<break/>(Africa)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">489</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1, 2, 4, others</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M-HCV</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SR</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95.7%<break/>(94&#x02013;97%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.7%<break/>(96&#x02013;99%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.75<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCV-HIV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(85&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">88.2%<break/>(74&#x02013;96%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.84<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCV-HBV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.4%<break/>(79&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.7%<break/>(88&#x02013;99%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.58<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.9%<break/>(87&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.8%<break/>(96&#x02013;99%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.60<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95.1%<break/>(82&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.8%<break/>(96&#x02013;99%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.88<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(94&#x02013;97%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.8%<break/>(96&#x02013;99%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.75<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hullegie et al. (2017) [<xref rid="B49-viruses-16-01863" ref-type="bibr">49</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Netherlands (Europe)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100% HIV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PM<break/>SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">89%<break/>(75&#x02013;96%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(85&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.97<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">22</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Mohamed et al. (2017) [<xref rid="B71-viruses-16-01863" ref-type="bibr">71</xref>]</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Tanzania<break/>(Africa)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">114</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1, 4</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">43.9% HIV<break/>9.8%<break/>HBV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SR</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.1%<break/>(95&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94.1%<break/>(82&#x02013;99%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.80<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">89</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DBS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81.7%<break/>(75&#x02013;87%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.9%<break/>(94&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.75<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rockstroh et al. (2017) [<xref rid="B72-viruses-16-01863" ref-type="bibr">72</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Germany<break/>(Europe)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">411</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(98&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(99&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.867<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Talal et al. (2017) [<xref rid="B73-viruses-16-01863" ref-type="bibr">73</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA<break/>(America)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">109</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1, 2, 3, 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.4% HIV<break/>100% Opioid use disorder</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.9%<break/>(89&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(94&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.88<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.01)</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">25</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Wasitthankasem et al.<break/>(2017) [<xref rid="B74-viruses-16-01863" ref-type="bibr">74</xref>]</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Thailand<break/>(Asia)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.3% HIV<break/>4.5% HBV</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">PM</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.905<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.854<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.870<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">290</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1, 3, 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99%<break/>(97&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(95&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.94<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adland et al. (2018) [<xref rid="B40-viruses-16-01863" ref-type="bibr">40</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UK<break/>(Europe)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">195</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1,3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95%<break/>(89&#x02013;98%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(95&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.55<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alonso et al. (2018) [<xref rid="B75-viruses-16-01863" ref-type="bibr">75</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spain<break/>(Europe)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">204</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1, 2, 3, 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.3% HIV<break/>27.9%<break/>HBV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">76.6%<break/>(95&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(95&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.951<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Benito et al. (2018) [<xref rid="B76-viruses-16-01863" ref-type="bibr">76</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spain<break/>(Europe)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90.91%<break/>(80&#x02013;97%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(80&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">29</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Chang et al. (2018) [<xref rid="B77-viruses-16-01863" ref-type="bibr">77</xref>]</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Taiwan<break/>(Asia)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">107</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SR</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.945<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">77</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.862<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">221</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1,2, others</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.0%<break/>(96&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(85&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.960<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">30</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Lamoury et al. (2018) [<xref rid="B51-viruses-16-01863" ref-type="bibr">51</xref>]</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Australia<break/>(Australia)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">119</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1, 2, 3, 6</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PM</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.7%<break/>(91&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(87&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.695<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">120</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DBS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">88.6%<break/>(80&#x02013;94%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97%<break/>(82&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.649<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">31</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Catlett et al. (2019) [<xref rid="B50-viruses-16-01863" ref-type="bibr">50</xref>]</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Australia<break/>(Australia)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">186</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PM</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.1%<break/>(90&#x02013;100%)<break/>100%<break/>(93&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(97&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.77<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">186</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DBS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90.7%<break/>(80&#x02013;97%)<break/>92.5%<break/>(82&#x02013;98%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(97&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.82<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kyuregyan et al. (2019) [<xref rid="B78-viruses-16-01863" ref-type="bibr">78</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Russia<break/>(Europe)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1, 3, others</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100<break/>(79&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(78&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.84<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.005)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">33</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">P&#x000e9;rez-Garc&#x000ed;a et al. (2019) [<xref rid="B42-viruses-16-01863" ref-type="bibr">42</xref>]</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Spain<break/>(Europe)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1, 2, 3, 4</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2.5% HIV</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">PM<break/>SR</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94.74%<break/>(82&#x02013;99%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(16&#x02013;100%)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.965<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">263</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90.62%<break/>(83&#x02013;96%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.20%<break/>(95&#x02013;100%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Suttichaimongkol et al.<break/>(2019) [<xref rid="B43-viruses-16-01863" ref-type="bibr">43</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thailand<break/>(Asia)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">165</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1, 3, 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.8% HIV<break/>1.8%HBV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PM<break/>SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95.3%<break/>(91&#x02013;98%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(81&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.8915<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">35</td><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Yu Xiang et al.<break/>(2019) [<xref rid="B79-viruses-16-01863" ref-type="bibr">79</xref>]</td><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">China<break/>(Asia)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">106</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1, 3, 6</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shandong Laibo Bio-chemical</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55.66%<break/>(46&#x02013;65%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(97&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(97&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1a</td><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SR</td><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.894<break/>(<italic toggle="yes">p</italic> = 0.04)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.360</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.400</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3b</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.500</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.122</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1b/3b</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.413</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.529</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">36</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Pollock et al. (2020) [<xref rid="B80-viruses-16-01863" ref-type="bibr">80</xref>]</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">UK<break/>(Europe)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">159</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">5% HIV<break/>0.5%HBV</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SR</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">79%<break/>(70&#x02013;86%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(91&#x02013;100%)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">126</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1, 2, 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87%<break/>(77&#x02013;93%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(91&#x02013;100%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">290</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1, 2, 3, 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">82.1%<break/>(77&#x02013;86%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.8%<break/>(99&#x02013;100%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wong et al. (2020) [<xref rid="B44-viruses-16-01863" ref-type="bibr">44</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Malaysia<break/>(Asia)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">112</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HD patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PM<break/>SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90.7%<break/>(83&#x02013;96%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(87&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.833<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">38</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Abid et al. (2021) [<xref rid="B81-viruses-16-01863" ref-type="bibr">81</xref>]</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Pakistan<break/>(Asia)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">200</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">PM</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;12 IU/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.8%<break/>(92&#x02013;99%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91.8%<break/>(83&#x02013;97%)</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">200</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1000 IU/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.0%<break/>(91&#x02013;99%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.2%<break/>(90&#x02013;100%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">200</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;3000 IU/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94.4%<break/>(88&#x02013;98%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.6%<break/>(92&#x02013;100%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">200</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG<break/>(10 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;12 IU/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.1%<break/>(95&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87.6%<break/>(78.4&#x02013;94%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">200</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1000 IU/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.1%<break/>(95&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93.8%<break/>(86&#x02013;98%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">200</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;3000 IU/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.1%<break/>(95&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.5%<break/>(91&#x02013;100%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chen et al. (2021) [<xref rid="B82-viruses-16-01863" ref-type="bibr">82</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Taiwan<break/>(Asia)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">412</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.46%<break/>(96&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.62%<break/>(96&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.964<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">40</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Kallala et al. (2021) [<xref rid="B45-viruses-16-01863" ref-type="bibr">45</xref>]</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Tunisia<break/>(Africa)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">PM<break/>SR</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.966<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">109</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1, 2, 3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95.05%<break/>(89&#x02013;98%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(63&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.958<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kannan et al. (2021) [<xref rid="B83-viruses-16-01863" ref-type="bibr">83</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">India<break/>(Asia)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">156</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect<break/>HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">77.35%<break/>(63&#x02013;87%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(96&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.872<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kumar et al. (2021) [<xref rid="B84-viruses-16-01863" ref-type="bibr">84</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Singapore<break/>(Asia)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">89</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PM<break/>SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect<break/>HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.4%<break/>(91&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(87&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.89<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kumbhar et al. (2021) [<xref rid="B85-viruses-16-01863" ref-type="bibr">85</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">India<break/>(Asia)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">208</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect<break/>HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91.58%<break/>(84&#x02013;96%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.12% <break/>(95&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.85<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ponnuvel et al. (2021) [<xref rid="B86-viruses-16-01863" ref-type="bibr">86</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">India<break/>(Asia)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">140</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1, 3, 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.42% HIV<break/>5.7%HBV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect<break/>HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80.62%<break/>(74&#x02013;88%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99%<break/>(95&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.927<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chuaypen et al. (2022) [<xref rid="B47-viruses-16-01863" ref-type="bibr">47</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thailand<break/>(Asia)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1, 2, 3, 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HD patient<break/>0%HIV<break/>0%HBV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94.9%<break/>(86&#x02013;99%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(90&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.956<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Le et al. (2022) [<xref rid="B87-viruses-16-01863" ref-type="bibr">87</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vietnam<break/>(Asia)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">102</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93.33%<break/>(78&#x02013;99%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91.67%<break/>(83&#x02013;97%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.64<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">47</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Sun et al. (2022) [<xref rid="B88-viruses-16-01863" ref-type="bibr">88</xref>]</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Taiwan<break/>(Asia)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">100% HIV<break/>9.9%HBV</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">PM</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">87.1%<break/>(77&#x02013;94%)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">99.4%<break/>(99&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.355<break/>(<italic toggle="yes">p</italic> = 0.089)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.806<break/>(<italic toggle="yes">p</italic> = 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.875<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">48</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Ponnuvel et al.<break/>(2023) [<xref rid="B89-viruses-16-01863" ref-type="bibr">89</xref>]</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">India<break/>(Asia)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">383</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1, 2, 4, 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PM</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.61%<break/>(94&#x02013;98%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(99&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.79<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1, 2, 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92.50%<break/>(80&#x02013;98%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(91&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.88<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Eid et al. (2023) [<xref rid="B90-viruses-16-01863" ref-type="bibr">90</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Egypt<break/>(Africa)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ELISA MyBioSource<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90%<break/>(76&#x02013;97%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(69&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.753<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">50</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Troyano-Hern&#x000e1;ez et al. (2023) [<xref rid="B52-viruses-16-01863" ref-type="bibr">52</xref>]</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Spain<break/>(Europe)</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">70</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1, 2, 3, 4, others</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SR</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">POC PCR<break/>Xpert HCV VL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(93&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(83&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.82<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DBS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(93&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%<break/>(83&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.90<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.90<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.82<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.81<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">51</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Vieira et al. (2023) [<xref rid="B91-viruses-16-01863" ref-type="bibr">91</xref>]</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Portugal<break/>(Europe)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">131</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SR</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;1000 IU/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.1%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02265;1000 IU/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93.8%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">88.9%<break/>(74&#x02013;97%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.1%<break/>(95&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.89<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Naveed et al. (2024) [<xref rid="B92-viruses-16-01863" ref-type="bibr">92</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pakistan<break/>(Asia)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">394</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0% HIV<break/>0.2%HBV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.0%<break/>(95&#x02013;99%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.6% <break/>(95&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.935<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Garg et al. (2024) [<xref rid="B93-viruses-16-01863" ref-type="bibr">93</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">India<break/>(Asia)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG<break/>(3 fmol/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">88.33%<break/>(77&#x02013;95%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100.00%<break/>(88&#x02013;100%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.93<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviation: CI: confidence interval; HBV: hepatitis B virus; HCV: hepatitis C virus; HIV: human immunodeficiency virus; HD: hemodialysis; IH: immunocompromised hosts; LTx: liver transplantation; NTx: kidney transplantation; N/A: no data available; POC: point of care; PM: plasma, SR: serum; Ref.: reference; UK: United Kingdom; USA: United States of America; w/o Tx: without transplantation.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec3dot2-viruses-16-01863"><title>3.2. HCVcAg as a Tool for Monitoring Treatment Response</title><p>In evaluating the monitoring value of HCVcAg versus HCV RNA during treatment, studies commonly report correlation coefficients, kappa indices, or concordance rates. These studies consistently demonstrate that HCVcAg levels decline more rapidly than HCV RNA levels following the initiation of treatment [<xref rid="B94-viruses-16-01863" ref-type="bibr">94</xref>]. However, the timing of assessments and the specific parameters monitored can vary across studies. Notably, a strong correlation between HCVcAg and the gold standard is often observed at the baseline [<xref rid="B95-viruses-16-01863" ref-type="bibr">95</xref>,<xref rid="B96-viruses-16-01863" ref-type="bibr">96</xref>,<xref rid="B97-viruses-16-01863" ref-type="bibr">97</xref>,<xref rid="B98-viruses-16-01863" ref-type="bibr">98</xref>]. During treatment, this correlation becomes more variable, possibly due to the rapid decline in viral load and differential responses based on genotype and host factors [<xref rid="B94-viruses-16-01863" ref-type="bibr">94</xref>,<xref rid="B95-viruses-16-01863" ref-type="bibr">95</xref>,<xref rid="B99-viruses-16-01863" ref-type="bibr">99</xref>]. Nevertheless, after treatment completion, the correlation strengthens, particularly at the 12- and 24-week sustained virologic response (SVR12 and SVR24) time points. In terms of agreement, the concordance between HCVcAg and the gold standard at the baseline and post-treatment is generally high, as indicated by correlation coefficients of 0.7 or greater, as shown in <xref rid="viruses-16-01863-t003" ref-type="table">Table 3</xref>. Additionally, kappa indices and concordance rates further support the utility of HCVcAg in monitoring treatment, especially in resource-limited settings. While the 2022 WHO guidelines do not specifically mention using HCVcAg to monitor DAA treatment, the EASL recommends that an undetectable HCV core antigen level at 12 or 24 weeks post-treatment can serve as a substitute for HCV RNA testing to determine SVR12 and SVR24, respectively. This recommendation applies to patients who had detectable HCV core antigen levels before starting treatment. The widespread adoption and implementation of this assay for monitoring treatment response is crucial for achieving the goal of HCV elimination by 2030, particularly in resource-limited settings.</p></sec><sec id="sec3dot3-viruses-16-01863"><title>3.3. The Advantages of HCVcAg Assays in Countries with Low-Resource Settings</title><p>HCVcAg assays offer several advantages in resource-limited settings, making them valuable tools in the fight against hepatitis C and achieving HCV elimination by 2030. First, the performance of the assay was noteworthy. As summarized in <xref rid="viruses-16-01863-t002" ref-type="table">Table 2</xref>, most studies demonstrated a good to excellent correlation between the HCVcAg and the gold standard HCV RNA assay. Second, HCVcAg assays are generally more cost-effective than NAT, the gold standard for HCV diagnosis. This makes them more accessible in settings with limited healthcare budgets. Specifically, Reyes-Mendez et al. demonstrated the economic benefits of using HCVcAg as a confirmatory test compared to HCV RNA. However, this benefit was more pronounced (USD 6.98 vs. USD 10.31) in areas with high HCV prevalence. In low prevalence settings, the cost advantage was less significant (USD 6.37 vs. USD 8.63) [<xref rid="B65-viruses-16-01863" ref-type="bibr">65</xref>]. Additionally, Kamal et al. reported that using HCVcAg to monitor treatments throughout their course resulted in cost savings of USD 860 compared to HCV RNA PCR monitoring. A combined HCVcAg and HCV RNA monitoring strategy also yielded USD 493.8 in savings compared with PCR alone [<xref rid="B67-viruses-16-01863" ref-type="bibr">67</xref>]. Wasitthankasem et al. compared the costs of two testing strategies. The first strategy involved immediate HCV RNA testing following a positive anti-HCV antibody test, with a total cost of USD 19,655. The second strategy involved confirming active infection with HCVcAg in samples with an anti-HCV antibody signal-to-cutoff ratio (S/CO) &#x02265; 5.0. Only samples with reactive anti-HCV antibodies and non-reactive HCVcAg were confirmed by HCV RNA testing; the total cost for this strategy was USD 10,213 [<xref rid="B74-viruses-16-01863" ref-type="bibr">74</xref>]. The economic value of HCVcAg is further highlighted by its simplified workflow and facilities compared to NAT, reducing the need for specialized equipment and highly trained personnel. This lowered the overall testing cost. Third, the accessibility of HCVcAg is expanding, with DBS testing simplifying sample collection, storage, and transport, which is crucial in areas with limited infrastructure. Troyano-Hern&#x000e1;ez et al. demonstrated a good correlation between HCVcAg and HCV RNA in dried serum and DBS samples [<xref rid="B52-viruses-16-01863" ref-type="bibr">52</xref>], although these sample types are not yet widely recommended for use. The reasons for this could be a lower analyte concentration in the DBS sample, variability introduced during collection and processing, potential effects on analyte stability during drying and storage, matrix effects from blood components, and less efficient elution of the antigen from the filter paper. These factors can collectively contribute to a reduced ability to accurately measure HCVcAg in DBS compared to plasma.</p></sec><sec id="sec3dot4-viruses-16-01863"><title>3.4. Weaknesses of Using HCVcAg in the Test-to-Treat Approach for HCV Infection</title><p>Similar to HCV RNA testing, HCVcAg can be used to detect active infections to initiate treatment. Although HCVcAg has a slightly lower sensitivity, in practice, its use in the field is not much different from NAT or RNA detection. The HCVcAg test is an immunoassay that requires specific equipments from the manufacturer to achieve rapid and accurate results. It cannot be performed manually at the point of care, and when performed in small quantities, testing costs increase because of the need for positive and negative controls for each run. Furthermore, the equipment or machines are typically available only in large hospitals. Currently, the market is a monopoly, with limited companies providing this test, and it is not suitable for POC testing. In contrast, there are qualitative HCV RNA tests at POC options, which makes them easier to use than HCVcAg. These POC devices utilize reverse transcriptase polymerase chain reaction technology to quickly identify the presence of the hepatitis C virus. With just a small blood sample from a fingertip, these tests can detect HCV RNA and provide results in approximately an hour. This rapid and convenient diagnostic capability is crucial for expanding access to HCV testing and facilitating timely treatment interventions, especially in decentralized healthcare settings.</p><p>In Thailand, the National Health Security Office (NHSO) issued guidelines in 2023 allowing the use of qualitative or quantitative HCV RNA tests as well as HCVcAg tests for diagnosis, treatment, and monitoring of treatment outcomes. In clinical practice, most healthcare providers rely on HCV RNA testing to initiate and monitor treatment. Despite advancements in combined HCVcAg and anti-HCV testing (Duo test), which is being developed for blood donor screening and to reduce the window period, the sensitivity of HCVcAg in the Duo test remains suboptimal. Specifically, a study by Ananchuensook et al. demonstrated that the sensitivity of the HCVcAg assay within the Duo test for diagnosing active infection and monitoring sustained virologic response (SVR) was 87.50% and 57.14%, respectively [<xref rid="B106-viruses-16-01863" ref-type="bibr">106</xref>]. Similarly, Kanokudom et al. evaluated the Duo test on 769 samples with various genotypes (1,3,6) and reported a sensitivity of 70.6% and a specificity of 100% for Duo/HCVcAg. Furthermore, this study found no statistically significant correlation between Duo/HCVcAg and HCV RNA [<xref rid="B107-viruses-16-01863" ref-type="bibr">107</xref>]. These findings suggest that the Duo test may have value in the diagnosis of chronic HCV infection. However, to enhance its utility in identifying active infection, further development is needed to improve the sensitivity of both the Duo test and standalone HCVcAg assays. Enhanced sensitivity, particularly in correlation with HCV RNA levels, will facilitate better-informed clinical decision-making and improve access to timely treatment. Therefore, despite the aforementioned strengths and limitations of HCVcAg in terms of sensitivity, leading global organizations (EASL, IDSA, AASLD, and the WHO) still consider it an alternative tool, with HCV RNA testing remaining the gold standard in clinical practice.</p></sec><sec id="sec3dot5-viruses-16-01863"><title>3.5. Challenges and Limitations of HCVcAg Testing</title><p>Although HCVcAg assays offer numerous advantages, they also present limitations and challenges that may hinder their widespread adoption in clinical practice. Firstly, the sensitivity of the assay is significantly influenced by viral load. This is evident in <xref rid="viruses-16-01863-t003" ref-type="table">Table 3</xref>, which shows a weak correlation between HCVcAg and HCV RNA during treatment and post-treatment follow-up with DAAs. Although studies have reported a high correlation in patients achieving SVR, the latest WHO guidelines (2022) recommend qualitative or quantitative HCV RNA testing for SVR monitoring. Secondly, assay specificity can be affected by the HCV genotype and subtype diversity. Sun et al. reported a lower correlation for genotype 1 compared to genotypes 2 and 3, possibly due to the quasispecies nature of HCV, suggesting that further investigation is needed [<xref rid="B88-viruses-16-01863" ref-type="bibr">88</xref>]. Data from Pollock et al. revealed that a significant proportion of HCV-infected individuals may be missed, with genotype 3 associated with an increased rate of false-negative results (OR = 3.59, 95% CI: 1.32&#x02013;9.71). These findings have implications for HCV diagnosis and treatment response monitoring, particularly in low- and middle-income regions where genotype 3 is prevalent [<xref rid="B80-viruses-16-01863" ref-type="bibr">80</xref>]. Furthermore, the high genetic variability of HCV can lead to amino acid changes in viral proteins, such as the core protein, potentially affecting their recognition by commercially available immunoassays. In a comprehensive study by Hansoongnern et al. (2023) [<xref rid="B108-viruses-16-01863" ref-type="bibr">108</xref>], a strong positive correlation between HCV RNA and HCVcAg was observed across all HCV genotypes (1a, 1b, 3a, and 6), with correlation coefficients ranging from 0.88 to 0.96 (<italic toggle="yes">p</italic> &#x0003c; 0.001). However, some samples, particularly those with genotypes 3a and 6, exhibited lower-than-expected HCVcAg levels compared to their corresponding HCV RNA values. Sequence analysis revealed that these samples carried amino acid substitutions at position 49 of the core protein, replacing threonine with alanine or valine. Mutations at this site may interfere with HCVcAg recognition by anti-HCV monoclonal antibodies [<xref rid="B108-viruses-16-01863" ref-type="bibr">108</xref>]. Thirdly, the cost-effectiveness of HCVcAg testing is most pronounced in populations with high HCV prevalence. Reyes et al. demonstrated that the cost of HCVcAg testing was USD 6.98 compared to USD 10.31 for HCV RNA in high-prevalence settings. In low prevalence areas, the cost advantage was less substantial (USD 6.37 vs. USD 8.63) or even negligible [<xref rid="B65-viruses-16-01863" ref-type="bibr">65</xref>]. Finally, WHO recommends laboratory-based HCVcAg assays for confirmatory diagnosis, which are typically performed on large platforms and may be difficult to implement in POC settings. In addition, immunoassays require calibration and internal quality control procedures. Operating small batches of tests while maintaining continuous quality assurance can increase the cost per test.</p></sec></sec><sec id="sec4-viruses-16-01863"><title>4. The Prospects in the Clinical Application of HCVcAg</title><sec id="sec4dot1-viruses-16-01863"><title>4.1. Predicting Disease Progression and Liver Damage</title><p>HCV infection can promote hepatic fibrosis through a complex molecular mechanism involving the upregulation of both transforming growth factor beta 1 (TGF-&#x003b2;1) and microRNA-192 (miR-192). This process is mediated by the HCV core protein, which stimulates the expression of miR-192 [<xref rid="B109-viruses-16-01863" ref-type="bibr">109</xref>]. Following upregulation, miR-192 is packaged into exosomes and transported to hematopoietic stem cells (HSCs) in the liver. The delivery of miR-192 to HSCs triggers the activation and subsequent production of fibrogenic markers, contributing to the development of liver fibrosis [<xref rid="B110-viruses-16-01863" ref-type="bibr">110</xref>].</p><p>The HCV core protein, an RNA-binding protein, exhibits multiple functions that contribute to HCV pathogenesis. It can independently induce hepatic steatosis, insulin resistance, and HCC [<xref rid="B111-viruses-16-01863" ref-type="bibr">111</xref>]. Furthermore, it stimulates hepatocyte proliferation and specific mutations within the core protein in genotype 1 patients associated with an elevated risk of HCC even after viral eradication [<xref rid="B112-viruses-16-01863" ref-type="bibr">112</xref>]. The HCV NS3 protein promotes hepatic fibrosis in chronic liver disease [<xref rid="B113-viruses-16-01863" ref-type="bibr">113</xref>], whereas NS5A plays a central role in viral replication and assembly. NS5 also contributes to hepatic steatosis, inhibits apoptosis, and confers resistance to interferon-&#x003b1; therapy. The progression of chronic HCV infection to HCC involves key cellular and molecular pathways, including the epidermal growth factor pathway [<xref rid="B114-viruses-16-01863" ref-type="bibr">114</xref>], signal transducer and activator of the transcription 3 pathway, transforming growth factor beta pathway, and vascular endothelial growth factor (VEGF) pathway [<xref rid="B115-viruses-16-01863" ref-type="bibr">115</xref>].</p><p>The HCV core protein exhibits multifaceted functionality, notably its ability to interact with cellular proto-oncogenes and disrupt their normal expression patterns. This disruption contributes significantly to the development of HCC, a common and serious consequence of chronic HCV infection. Extensive research has highlighted the core protein&#x02019;s pivotal role in manipulating various signaling pathways crucial to HCC development. These pathways include transforming growth factor &#x003b2; (TGF-&#x003b2;), nuclear factor &#x003ba;B (NF-&#x003ba;B), tumor necrosis factor &#x003b1; (TNF-&#x003b1;), cyclooxygenase-2 (COX-2), Wnt/&#x003b2;-catenin (WNT), vascular endothelial growth factor (VEGF), and peroxisome proliferator-activated receptor &#x003b1; (PPAR&#x003b1;) [<xref rid="B116-viruses-16-01863" ref-type="bibr">116</xref>,<xref rid="B117-viruses-16-01863" ref-type="bibr">117</xref>,<xref rid="B118-viruses-16-01863" ref-type="bibr">118</xref>]. The intricate mechanisms by which the core protein modulates these pathways remain an area of active investigation. A deeper understanding of the molecular interplay between the HCV core protein and these signaling pathways is essential for developing effective strategies to prevent HCV-related HCC. Given its involvement in HCC pathogenesis, the HCV core antigen (HCVcAg) holds promise as a valuable molecular target for both research and clinical monitoring. By tracking HCVcAg levels, clinicians can potentially identify individuals at a higher risk of developing adverse hepatic outcomes, such as cirrhosis and HCC, following HCV infection. This knowledge could facilitate early intervention and improve patient outcomes.</p></sec><sec id="sec4dot2-viruses-16-01863"><title>4.2. Simplifying HCV Diagnosis</title><p>While HCVcAg is recommended as a biomarker for both diagnosis and treatment monitoring in reputable guidelines, its use remains limited. Current HCVcAg assays require centralized laboratory testing with immunoassay systems and are restricted to serum or plasma samples. To achieve HCV elimination by 2030, a key strategy involves simplifying the diagnostic process to facilitate earlier treatment initiation with DAAs.</p><p>The WHO has proposed a combined anti-HCV and HCVcAg assay to optimize the diagnostic pathway and enhance accuracy [<xref rid="B119-viruses-16-01863" ref-type="bibr">119</xref>]. Furthermore, the development of RDTs or POC tests represents a critical trend and strategy for expanding HCVcAg testing. Addressing these needs, Daktari Diagnostics, based in Boston, is developing a novel, rapid, and affordable POC diagnostic tool for HCV. This system utilizes microfluidic technology to detect HCVcAg from a single drop of blood, delivering results within 30 min using a portable cartridge [<xref rid="B120-viruses-16-01863" ref-type="bibr">120</xref>]. This technology, also under development for HIV, holds significant promise for resource-constrained settings, particularly in low- and middle-income countries. Despite its promising potential, HCV presents a challenge due to its highly diverse nature. Continuous mutations within the viral genome can alter the structure of the core protein, potentially hindering its detection by antibodies in diagnostic kits, leading to false-negative results. As demonstrated by Hansoongnern et al., amino acid changes in the core protein were observed in HCVcAg-negative samples [<xref rid="B108-viruses-16-01863" ref-type="bibr">108</xref>]. Encouragingly, according to author Chen, a strong correlation persists between HCVcAg and HCV RNA, even in the presence of common resistance-associated substitutions (RASs) like Y93H, V179I, Q80K, S122G, and C316N, which were prevalent in the era of DAAs [<xref rid="B121-viruses-16-01863" ref-type="bibr">121</xref>]. This suggests that developing highly accurate HCVcAg assays that can adapt to these viral variations remains a crucial strategy for achieving HCV elimination.</p></sec></sec><sec sec-type="conclusions" id="sec5-viruses-16-01863"><title>5. Conclusions and Potential Future Applications</title><p>HCVcAg has significant potential for expanding access to hepatitis C diagnosis and care, especially in resource-limited settings. As a valuable tool for screening, diagnosing, and monitoring hepatitis C, HCVcAg closely aligns with HCV RNA levels, offering a cost-effective and efficient alternative for managing the infection. While its sensitivity can be influenced by genetic variations in the core protein across different genotypes, ongoing advancements in test sensitivity, standardization, and POC applications make HCVcAg testing increasingly vital. This is particularly true for low- and middle-income countries striving to meet the WHO&#x02019;s 2030 hepatitis C elimination goals. Beyond its role in diagnosis and monitoring, HCVcAg also impacts liver disease by contributing to liver fibrosis and affecting pathways that can lead to liver cancer.</p><p>Looking ahead, with the application of advancements in science and technology, particularly artificial intelligence, HCVcAg is expected to play an even greater role in treatment monitoring and potentially even in predicting treatment response. An example lies in the advancements in nanotechnology, which offers several key advantages over traditional methods like EIA. Firstly, they typically exhibit a higher sensitivity, enabling the detection of lower concentrations of target molecules, such as viral antigens or antibodies. This is attributed to the unique properties of nanomaterials, allowing for signal amplification and improved binding efficiency. Secondly, nanotechnology-based assays can be faster and require smaller sample volumes, leading to quicker turnaround times and reduced costs. Thirdly, these assays often demonstrate enhanced specificity, minimizing cross-reactivity and false-positive results. Finally, nanotechnology allows for the development of flexible and miniaturized platforms, facilitating point-of-care testing and integration with lab-on-a-chip devices. Together, these advantages position nanotechnology-based assays as powerful tools for disease diagnosis and monitoring. In conclusion, as technology and artificial intelligence progress, leading to decreased costs and wider accessibility, HCVcAg testing is poised to become a cornerstone in global efforts to eliminate hepatitis C.</p></sec></body><back><ack><title>Acknowledgments</title><p>We gratefully acknowledge all the staff at the Center of Excellence in the Clinical Virology and International program of Medical Sciences, Faculty of Medicine, Chulalongkorn University.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, Y.P. and D.H.H.L.; methodology, Y.P., D.H.H.L., S.K. and S.V.; formal analysis, Y.P., D.H.H.L. and H.M.N.; screening paper and collecting data, Y.P., D.H.H.L., S.K., S.H. and R.Y.; writing&#x02014;original draft preparation, Y.P. and D.H.H.L.; writing&#x02014;review and editing, Y.P., D.H.H.L., S.K., S.H. and H.M.N.; supervision, project administration, and funding acquisition, Y.P. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-16-01863"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Lo</surname><given-names>S.</given-names></name>
</person-group><article-title>Hepatitis C virus: Virology, diagnosis and treatment</article-title><source>World J. Hepatol.</source><year>2015</year><volume>7</volume><fpage>1377</fpage><pub-id pub-id-type="doi">10.4254/wjh.v7.i10.1377</pub-id><pub-id pub-id-type="pmid">26052383</pub-id>
</element-citation></ref><ref id="B2-viruses-16-01863"><label>2.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><source>Global Health Sector Strategies on, Respectively, HIV, Viral Hepatitis and Sexually Transmitted Infections for the Period 2022&#x02013;2030</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2022</year><fpage>19</fpage><isbn>978-92-4-005377-9</isbn></element-citation></ref><ref id="B3-viruses-16-01863"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pecoraro</surname><given-names>V.</given-names></name>
<name><surname>Banzi</surname><given-names>R.</given-names></name>
<name><surname>Cariani</surname><given-names>E.</given-names></name>
<name><surname>Chester</surname><given-names>J.</given-names></name>
<name><surname>Villa</surname><given-names>E.</given-names></name>
<name><surname>D&#x02019;Amico</surname><given-names>R.</given-names></name>
<name><surname>Trenti</surname><given-names>T.</given-names></name>
</person-group><article-title>New direct-acting antivirals for the treatment of patients with hepatitis C virus infection: A systematic review of randomized controlled trials</article-title><source>J. Clin. Exp. Hepatol.</source><year>2019</year><volume>9</volume><fpage>522</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1016/j.jceh.2018.07.004</pub-id><pub-id pub-id-type="pmid">31516269</pub-id>
</element-citation></ref><ref id="B4-viruses-16-01863"><label>4.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Deniz</surname><given-names>M.T.</given-names></name>
<name><surname>Akhan</surname><given-names>S.</given-names></name>
</person-group><article-title>Hepatitis C Virus Structure and Diagnostic Methods</article-title><source>Hepatitis C-Recent Advances</source><person-group person-group-type="editor">
<name><surname>Qi</surname><given-names>X.</given-names></name>
<name><surname>Yang</surname><given-names>L.</given-names></name>
</person-group><publisher-name>IntechOpen</publisher-name><publisher-loc>London, UK</publisher-loc><year>2023</year><isbn>978-1-83769-557-7</isbn></element-citation></ref><ref id="B5-viruses-16-01863"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roger</surname><given-names>S.</given-names></name>
<name><surname>Ducancelle</surname><given-names>A.</given-names></name>
<name><surname>Le Guillou-Guillemette</surname><given-names>H.</given-names></name>
<name><surname>Gaudy</surname><given-names>C.</given-names></name>
<name><surname>Lunel</surname><given-names>F.</given-names></name>
</person-group><article-title>HCV virology and diagnosis</article-title><source>Clin. Res. Hepatol. Gastroenterol.</source><year>2021</year><volume>45</volume><fpage>101626</fpage><pub-id pub-id-type="doi">10.1016/j.clinre.2021.101626</pub-id><pub-id pub-id-type="pmid">33636428</pub-id>
</element-citation></ref><ref id="B6-viruses-16-01863"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Okamoto</surname><given-names>H.</given-names></name>
<name><surname>Kojima</surname><given-names>M.</given-names></name>
<name><surname>Okada</surname><given-names>S.-I.</given-names></name>
<name><surname>Yoshizawa</surname><given-names>H.</given-names></name>
<name><surname>Iizuka</surname><given-names>H.</given-names></name>
<name><surname>Tanaka</surname><given-names>T.</given-names></name>
<name><surname>Muchmore</surname><given-names>E.E.</given-names></name>
<name><surname>Peterson</surname><given-names>D.A.</given-names></name>
<name><surname>Ito</surname><given-names>Y.</given-names></name>
<name><surname>Mishiro</surname><given-names>S.</given-names></name>
</person-group><article-title>Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: Variability and stability</article-title><source>Virology</source><year>1992</year><volume>190</volume><fpage>894</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1016/0042-6822(92)90933-G</pub-id><pub-id pub-id-type="pmid">1325713</pub-id>
</element-citation></ref><ref id="B7-viruses-16-01863"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tsukiyama-Kohara</surname><given-names>K.</given-names></name>
<name><surname>Kohara</surname><given-names>M.</given-names></name>
</person-group><article-title>Hepatitis C Virus: Viral Quasispecies and Genotypes</article-title><source>Int. J. Mol. Sci.</source><year>2017</year><volume>19</volume><elocation-id>23</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19010023</pub-id><pub-id pub-id-type="pmid">29271914</pub-id>
</element-citation></ref><ref id="B8-viruses-16-01863"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sevvana</surname><given-names>M.</given-names></name>
<name><surname>Keck</surname><given-names>Z.</given-names></name>
<name><surname>Foung</surname><given-names>S.K.</given-names></name>
<name><surname>Kuhn</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Structural perspectives on HCV humoral immune evasion mechanisms</article-title><source>Curr. Opin. Virol.</source><year>2021</year><volume>49</volume><fpage>92</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2021.05.002</pub-id><pub-id pub-id-type="pmid">34091143</pub-id>
</element-citation></ref><ref id="B9-viruses-16-01863"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>D.B.</given-names></name>
<name><surname>Bukh</surname><given-names>J.</given-names></name>
<name><surname>Kuiken</surname><given-names>C.</given-names></name>
<name><surname>Muerhoff</surname><given-names>A.S.</given-names></name>
<name><surname>Rice</surname><given-names>C.M.</given-names></name>
<name><surname>Stapleton</surname><given-names>J.T.</given-names></name>
<name><surname>Simmonds</surname><given-names>P.</given-names></name>
</person-group><article-title>Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource</article-title><source>Hepatology</source><year>2014</year><volume>59</volume><fpage>318</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1002/hep.26744</pub-id><pub-id pub-id-type="pmid">24115039</pub-id>
</element-citation></ref><ref id="B10-viruses-16-01863"><label>10.</label><element-citation publication-type="webpage"><article-title>ICTV</article-title><comment>Available online: <ext-link xlink:href="https://ictv.global/sg_wiki/flaviviridae/hepacivirus/table1" ext-link-type="uri">https://ictv.global/sg_wiki/flaviviridae/hepacivirus/table1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-17">(accessed on 17 October 2024)</date-in-citation></element-citation></ref><ref id="B11-viruses-16-01863"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Borgia</surname><given-names>S.M.</given-names></name>
<name><surname>Hedskog</surname><given-names>C.</given-names></name>
<name><surname>Parhy</surname><given-names>B.</given-names></name>
<name><surname>Hyland</surname><given-names>R.H.</given-names></name>
<name><surname>Stamm</surname><given-names>L.M.</given-names></name>
<name><surname>Brainard</surname><given-names>D.M.</given-names></name>
<name><surname>Subramanian</surname><given-names>M.G.</given-names></name>
<name><surname>McHutchison</surname><given-names>J.G.</given-names></name>
<name><surname>Mo</surname><given-names>H.</given-names></name>
<name><surname>Svarovskaia</surname><given-names>E.</given-names></name>
</person-group><article-title>Identification of a novel hepatitis C virus genotype from Punjab, India: Expanding classification of hepatitis C virus into 8 genotypes</article-title><source>J. Infect. Dis.</source><year>2018</year><volume>218</volume><fpage>1722</fpage><lpage>1729</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiy401</pub-id><pub-id pub-id-type="pmid">29982508</pub-id>
</element-citation></ref><ref id="B12-viruses-16-01863"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Simmonds</surname><given-names>P.</given-names></name>
<name><surname>Bukh</surname><given-names>J.</given-names></name>
<name><surname>Combet</surname><given-names>C.</given-names></name>
<name><surname>Del&#x000e9;age</surname><given-names>G.</given-names></name>
<name><surname>Enomoto</surname><given-names>N.</given-names></name>
<name><surname>Feinstone</surname><given-names>S.</given-names></name>
<name><surname>Halfon</surname><given-names>P.</given-names></name>
<name><surname>Inchausp&#x000e9;</surname><given-names>G.</given-names></name>
<name><surname>Kuiken</surname><given-names>C.</given-names></name>
<name><surname>Maertens</surname><given-names>G.</given-names></name>
</person-group><article-title>Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes</article-title><source>Hepatology</source><year>2005</year><volume>42</volume><fpage>962</fpage><lpage>973</lpage><pub-id pub-id-type="doi">10.1002/hep.20819</pub-id><pub-id pub-id-type="pmid">16149085</pub-id>
</element-citation></ref><ref id="B13-viruses-16-01863"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lefkowitz</surname><given-names>E.J.</given-names></name>
<name><surname>Dempsey</surname><given-names>D.M.</given-names></name>
<name><surname>Hendrickson</surname><given-names>R.C.</given-names></name>
<name><surname>Orton</surname><given-names>R.J.</given-names></name>
<name><surname>Siddell</surname><given-names>S.G.</given-names></name>
<name><surname>Smith</surname><given-names>D.B.</given-names></name>
</person-group><article-title>Virus taxonomy: The database of the International Committee on Taxonomy of Viruses (ICTV)</article-title><source>Nucleic Acids Res.</source><year>2018</year><volume>46</volume><fpage>D708</fpage><lpage>D717</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx932</pub-id><pub-id pub-id-type="pmid">29040670</pub-id>
</element-citation></ref><ref id="B14-viruses-16-01863"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Murphy</surname><given-names>D.G.</given-names></name>
<name><surname>Sablon</surname><given-names>E.</given-names></name>
<name><surname>Chamberland</surname><given-names>J.</given-names></name>
<name><surname>Fournier</surname><given-names>E.</given-names></name>
<name><surname>Dandavino</surname><given-names>R.</given-names></name>
<name><surname>Tremblay</surname><given-names>C.L.</given-names></name>
</person-group><article-title>Hepatitis C virus genotype 7, a new genotype originating from central Africa</article-title><source>J. Clin. Microbiol.</source><year>2015</year><volume>53</volume><fpage>967</fpage><lpage>972</lpage><pub-id pub-id-type="doi">10.1128/JCM.02831-14</pub-id><pub-id pub-id-type="pmid">25520447</pub-id>
</element-citation></ref><ref id="B15-viruses-16-01863"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wasitthankasem</surname><given-names>R.</given-names></name>
<name><surname>Vongpunsawad</surname><given-names>S.</given-names></name>
<name><surname>Siripon</surname><given-names>N.</given-names></name>
<name><surname>Suya</surname><given-names>C.</given-names></name>
<name><surname>Chulothok</surname><given-names>P.</given-names></name>
<name><surname>Chaiear</surname><given-names>K.</given-names></name>
<name><surname>Rujirojindakul</surname><given-names>P.</given-names></name>
<name><surname>Kanjana</surname><given-names>S.</given-names></name>
<name><surname>Theamboonlers</surname><given-names>A.</given-names></name>
<name><surname>Tangkijvanich</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Genotypic distribution of hepatitis C virus in Thailand and Southeast Asia</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><fpage>e0126764</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0126764</pub-id><pub-id pub-id-type="pmid">25962112</pub-id>
</element-citation></ref><ref id="B16-viruses-16-01863"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yasui</surname><given-names>K.</given-names></name>
<name><surname>Wakita</surname><given-names>T.</given-names></name>
<name><surname>Tsukiyama-Kohara</surname><given-names>K.</given-names></name>
<name><surname>Funahashi</surname><given-names>S.-I.</given-names></name>
<name><surname>Ichikawa</surname><given-names>M.</given-names></name>
<name><surname>Kajita</surname><given-names>T.</given-names></name>
<name><surname>Moradpour</surname><given-names>D.</given-names></name>
<name><surname>Wands</surname><given-names>J.R.</given-names></name>
<name><surname>Kohara</surname><given-names>M.</given-names></name>
</person-group><article-title>The native form and maturation process of hepatitis C virus core protein</article-title><source>J. Virol.</source><year>1998</year><volume>72</volume><fpage>6048</fpage><lpage>6055</lpage><pub-id pub-id-type="doi">10.1128/JVI.72.7.6048-6055.1998</pub-id><pub-id pub-id-type="pmid">9621068</pub-id>
</element-citation></ref><ref id="B17-viruses-16-01863"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gawlik</surname><given-names>K.</given-names></name>
<name><surname>Gallay</surname><given-names>P.A.</given-names></name>
</person-group><article-title>HCV core protein and virus assembly: What we know without structures</article-title><source>Immunol. Res.</source><year>2014</year><volume>60</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1007/s12026-014-8494-3</pub-id><pub-id pub-id-type="pmid">24557493</pub-id>
</element-citation></ref><ref id="B18-viruses-16-01863"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hourioux</surname><given-names>C.</given-names></name>
<name><surname>Ait-Goughoulte</surname><given-names>M.</given-names></name>
<name><surname>Patient</surname><given-names>R.</given-names></name>
<name><surname>Fouquenet</surname><given-names>D.</given-names></name>
<name><surname>Arcanger-Doudet</surname><given-names>F.</given-names></name>
<name><surname>Brand</surname><given-names>D.</given-names></name>
<name><surname>Martin</surname><given-names>A.</given-names></name>
<name><surname>Roingeard</surname><given-names>P.</given-names></name>
</person-group><article-title>Core protein domains involved in hepatitis C virus-like particle assembly and budding at the endoplasmic reticulum membrane</article-title><source>Cell. Microbiol.</source><year>2007</year><volume>9</volume><fpage>1014</fpage><lpage>1027</lpage><pub-id pub-id-type="doi">10.1111/j.1462-5822.2006.00848.x</pub-id><pub-id pub-id-type="pmid">17257269</pub-id>
</element-citation></ref><ref id="B19-viruses-16-01863"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Santolini</surname><given-names>E.</given-names></name>
<name><surname>Migliaccio</surname><given-names>G.</given-names></name>
<name><surname>La Monica</surname><given-names>N.</given-names></name>
</person-group><article-title>Biosynthesis and biochemical properties of the hepatitis C virus core protein</article-title><source>J. Virol.</source><year>1994</year><volume>68</volume><fpage>3631</fpage><lpage>3641</lpage><pub-id pub-id-type="doi">10.1128/jvi.68.6.3631-3641.1994</pub-id><pub-id pub-id-type="pmid">8189501</pub-id>
</element-citation></ref><ref id="B20-viruses-16-01863"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morozov</surname><given-names>V.A.</given-names></name>
<name><surname>Lagaye</surname><given-names>S.</given-names></name>
</person-group><article-title>Hepatitis C virus: Morphogenesis, infection and therapy</article-title><source>World J. Hepatol.</source><year>2018</year><volume>10</volume><fpage>186</fpage><pub-id pub-id-type="doi">10.4254/wjh.v10.i2.186</pub-id><pub-id pub-id-type="pmid">29527256</pub-id>
</element-citation></ref><ref id="B21-viruses-16-01863"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Manns</surname><given-names>M.P.</given-names></name>
<name><surname>Maasoumy</surname><given-names>B.</given-names></name>
</person-group><article-title>Breakthroughs in hepatitis C research: From discovery to cure</article-title><source>Nat. Rev. Gastroenterol. Hepatol.</source><year>2022</year><volume>19</volume><fpage>533</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1038/s41575-022-00608-8</pub-id><pub-id pub-id-type="pmid">35595834</pub-id>
</element-citation></ref><ref id="B22-viruses-16-01863"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Targett-Adams</surname><given-names>P.</given-names></name>
<name><surname>Hope</surname><given-names>G.</given-names></name>
<name><surname>Boulant</surname><given-names>S.</given-names></name>
<name><surname>McLauchlan</surname><given-names>J.</given-names></name>
</person-group><article-title>Maturation of hepatitis C virus core protein by signal peptide peptidase is required for virus production</article-title><source>J. Biol. Chem.</source><year>2008</year><volume>283</volume><fpage>16850</fpage><lpage>16859</lpage><pub-id pub-id-type="doi">10.1074/jbc.M802273200</pub-id><pub-id pub-id-type="pmid">18424431</pub-id>
</element-citation></ref><ref id="B23-viruses-16-01863"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Masaki</surname><given-names>T.</given-names></name>
<name><surname>Suzuki</surname><given-names>R.</given-names></name>
<name><surname>Murakami</surname><given-names>K.</given-names></name>
<name><surname>Aizaki</surname><given-names>H.</given-names></name>
<name><surname>Ishii</surname><given-names>K.</given-names></name>
<name><surname>Murayama</surname><given-names>A.</given-names></name>
<name><surname>Date</surname><given-names>T.</given-names></name>
<name><surname>Matsuura</surname><given-names>Y.</given-names></name>
<name><surname>Miyamura</surname><given-names>T.</given-names></name>
<name><surname>Wakita</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles</article-title><source>J. Virol.</source><year>2008</year><volume>82</volume><fpage>7964</fpage><lpage>7976</lpage><pub-id pub-id-type="doi">10.1128/JVI.00826-08</pub-id><pub-id pub-id-type="pmid">18524832</pub-id>
</element-citation></ref><ref id="B24-viruses-16-01863"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shavinskaya</surname><given-names>A.</given-names></name>
<name><surname>Boulant</surname><given-names>S.</given-names></name>
<name><surname>Penin</surname><given-names>F.</given-names></name>
<name><surname>McLauchlan</surname><given-names>J.</given-names></name>
<name><surname>Bartenschlager</surname><given-names>R.</given-names></name>
</person-group><article-title>The lipid droplet binding domain of hepatitis C virus core protein is a major determinant for efficient virus assembly</article-title><source>J. Biol. Chem.</source><year>2007</year><volume>282</volume><fpage>37158</fpage><lpage>37169</lpage><pub-id pub-id-type="doi">10.1074/jbc.M707329200</pub-id><pub-id pub-id-type="pmid">17942391</pub-id>
</element-citation></ref><ref id="B25-viruses-16-01863"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Herker</surname><given-names>E.</given-names></name>
<name><surname>Harris</surname><given-names>C.</given-names></name>
<name><surname>Hernandez</surname><given-names>C.</given-names></name>
<name><surname>Carpentier</surname><given-names>A.</given-names></name>
<name><surname>Kaehlcke</surname><given-names>K.</given-names></name>
<name><surname>Rosenberg</surname><given-names>A.R.</given-names></name>
<name><surname>Farese Jr</surname><given-names>R.V.</given-names></name>
<name><surname>Ott</surname><given-names>M.</given-names></name>
</person-group><article-title>Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1</article-title><source>Nat. Med.</source><year>2010</year><volume>16</volume><fpage>1295</fpage><lpage>1298</lpage><pub-id pub-id-type="doi">10.1038/nm.2238</pub-id><pub-id pub-id-type="pmid">20935628</pub-id>
</element-citation></ref><ref id="B26-viruses-16-01863"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Menzel</surname><given-names>N.</given-names></name>
<name><surname>Fischl</surname><given-names>W.</given-names></name>
<name><surname>Hueging</surname><given-names>K.</given-names></name>
<name><surname>Bankwitz</surname><given-names>D.</given-names></name>
<name><surname>Frentzen</surname><given-names>A.</given-names></name>
<name><surname>Haid</surname><given-names>S.</given-names></name>
<name><surname>Gentzsch</surname><given-names>J.</given-names></name>
<name><surname>Kaderali</surname><given-names>L.</given-names></name>
<name><surname>Bartenschlager</surname><given-names>R.</given-names></name>
<name><surname>Pietschmann</surname><given-names>T.</given-names></name>
</person-group><article-title>MAP-kinase regulated cytosolic phospholipase A2 activity is essential for production of infectious hepatitis C virus particles</article-title><source>PLoS Pathog.</source><year>2012</year><volume>8</volume><fpage>e1002829</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1002829</pub-id><pub-id pub-id-type="pmid">22911431</pub-id>
</element-citation></ref><ref id="B27-viruses-16-01863"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Q.</given-names></name>
<name><surname>P&#x000e8;ne</surname><given-names>V.</given-names></name>
<name><surname>Krishnamurthy</surname><given-names>S.</given-names></name>
<name><surname>Cha</surname><given-names>H.</given-names></name>
<name><surname>Liang</surname><given-names>T.J.</given-names></name>
</person-group><article-title>Hepatitis C virus infection activates an innate pathway involving IKK-&#x003b1; in lipogenesis and viral assembly</article-title><source>Nat. Med.</source><year>2013</year><volume>19</volume><fpage>722</fpage><lpage>729</lpage><pub-id pub-id-type="doi">10.1038/nm.3190</pub-id><pub-id pub-id-type="pmid">23708292</pub-id>
</element-citation></ref><ref id="B28-viruses-16-01863"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Neveu</surname><given-names>G.</given-names></name>
<name><surname>Barouch-Bentov</surname><given-names>R.</given-names></name>
<name><surname>Ziv-Av</surname><given-names>A.</given-names></name>
<name><surname>Gerber</surname><given-names>D.</given-names></name>
<name><surname>Jacob</surname><given-names>Y.</given-names></name>
<name><surname>Einav</surname><given-names>S.</given-names></name>
</person-group><article-title>Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly</article-title><source>Hepatology</source><year>2012</year><volume>56</volume><fpage>e1002845</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1002845</pub-id><pub-id pub-id-type="pmid">22916011</pub-id>
</element-citation></ref><ref id="B29-viruses-16-01863"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Neveu</surname><given-names>G.</given-names></name>
<name><surname>Ziv-Av</surname><given-names>A.</given-names></name>
<name><surname>Barouch-Bentov</surname><given-names>R.</given-names></name>
<name><surname>Berkerman</surname><given-names>E.</given-names></name>
<name><surname>Mulholland</surname><given-names>J.</given-names></name>
<name><surname>Einav</surname><given-names>S.</given-names></name>
</person-group><article-title>AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets</article-title><source>J. Virol.</source><year>2015</year><volume>89</volume><fpage>4387</fpage><lpage>4404</lpage><pub-id pub-id-type="doi">10.1128/JVI.02705-14</pub-id><pub-id pub-id-type="pmid">25653444</pub-id>
</element-citation></ref><ref id="B30-viruses-16-01863"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Freiman</surname><given-names>J.M.</given-names></name>
<name><surname>Tran</surname><given-names>T.M.</given-names></name>
<name><surname>Schumacher</surname><given-names>S.G.</given-names></name>
<name><surname>White</surname><given-names>L.F.</given-names></name>
<name><surname>Ongarello</surname><given-names>S.</given-names></name>
<name><surname>Cohn</surname><given-names>J.</given-names></name>
<name><surname>Easterbrook</surname><given-names>P.J.</given-names></name>
<name><surname>Linas</surname><given-names>B.P.</given-names></name>
<name><surname>Denkinger</surname><given-names>C.M.</given-names></name>
</person-group><article-title>Hepatitis C Core Antigen Testing for Diagnosis of Hepatitis C Virus Infection: A Systematic Review and Meta-analysis</article-title><source>Ann. Intern. Med.</source><year>2016</year><volume>165</volume><fpage>345</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.7326/M16-0065</pub-id><pub-id pub-id-type="pmid">27322622</pub-id>
</element-citation></ref><ref id="B31-viruses-16-01863"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khan</surname><given-names>H.</given-names></name>
<name><surname>Hill</surname><given-names>A.</given-names></name>
<name><surname>Main</surname><given-names>J.</given-names></name>
<name><surname>Brown</surname><given-names>A.</given-names></name>
<name><surname>Cooke</surname><given-names>G.</given-names></name>
</person-group><article-title>Can hepatitis C virus antigen testing replace ribonucleic acid polymerase chain reaction analysis for detecting hepatitis C virus? A systematic review</article-title><source>Open Forum Infect. Dis.</source><year>2017</year><volume>4</volume><fpage>ofw252</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofw252</pub-id><pub-id pub-id-type="pmid">28567430</pub-id>
</element-citation></ref><ref id="B32-viruses-16-01863"><label>32.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><source>New Recommendation on Hepatitis C Virus Testing and Treatment for People at Ongoing Risk of Infection: Policy Brief</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2023</year><isbn>978-92-4-007187-2</isbn></element-citation></ref><ref id="B33-viruses-16-01863"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Warkad</surname><given-names>S.D.</given-names></name>
<name><surname>Song</surname><given-names>K.S.</given-names></name>
<name><surname>Pal</surname><given-names>D.</given-names></name>
<name><surname>Nimse</surname><given-names>S.B.</given-names></name>
</person-group><article-title>Developments in the HCV Screening Technologies Based on the Detection of Antigens and Antibodies</article-title><source>Sensors</source><year>2019</year><volume>19</volume><elocation-id>4257</elocation-id><pub-id pub-id-type="doi">10.3390/s19194257</pub-id><pub-id pub-id-type="pmid">31575036</pub-id>
</element-citation></ref><ref id="B34-viruses-16-01863"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Shen</surname><given-names>X.</given-names></name>
</person-group><article-title>Development of a nucleic acid lateral flow strip for detection of hepatitis C virus (HCV) core antigen</article-title><source>Nucleosides Nucleotides Nucleic Acids</source><year>2013</year><volume>32</volume><fpage>59</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1080/15257770.2013.763976</pub-id><pub-id pub-id-type="pmid">23448141</pub-id>
</element-citation></ref><ref id="B35-viruses-16-01863"><label>35.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>AASLD-IDSA</collab>
</person-group><article-title>Recommendations for Testing, Managing, and Treating Hepatitis C</article-title><comment>Available online: <ext-link xlink:href="http://www.hcvguidelines.org" ext-link-type="uri">http://www.hcvguidelines.org</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-25">(accessed on 25 November 2024)</date-in-citation></element-citation></ref><ref id="B36-viruses-16-01863"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pawlotsky</surname><given-names>J.-M.</given-names></name>
<name><surname>Negro</surname><given-names>F.</given-names></name>
<name><surname>Aghemo</surname><given-names>A.</given-names></name>
<name><surname>Berenguer</surname><given-names>M.</given-names></name>
<name><surname>Dalgard</surname><given-names>O.</given-names></name>
<name><surname>Dusheiko</surname><given-names>G.</given-names></name>
<name><surname>Marra</surname><given-names>F.</given-names></name>
<name><surname>Puoti</surname><given-names>M.</given-names></name>
<name><surname>Wedemeyer</surname><given-names>H.</given-names></name>
</person-group><article-title>EASL recommendations on treatment of hepatitis C: Final update of the series</article-title><source>J. Hepatol.</source><year>2020</year><volume>73</volume><fpage>1170</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2020.08.018</pub-id><pub-id pub-id-type="pmid">32956768</pub-id>
</element-citation></ref><ref id="B37-viruses-16-01863"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bhattacharya</surname><given-names>D.</given-names></name>
<name><surname>Aronsohn</surname><given-names>A.</given-names></name>
<name><surname>Price</surname><given-names>J.</given-names></name>
<name><surname>Lo Re</surname><given-names>V.</given-names><suffix>III</suffix></name>
</person-group><article-title>Hepatitis C guidance 2023 update: American Association for the Study of Liver diseases&#x02013;infectious diseases society of America recommendations for testing, managing, and treating hepatitis c virus infection</article-title><source>Clin. Infect. Dis.</source><year>2023</year><fpage>ciad319</fpage><pub-id pub-id-type="doi">10.1093/cid/ciad319</pub-id><pub-id pub-id-type="pmid">37229695</pub-id>
</element-citation></ref><ref id="B38-viruses-16-01863"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hosseini-Moghaddam</surname><given-names>S.</given-names></name>
<name><surname>Iran-Pour</surname><given-names>E.</given-names></name>
<name><surname>Rotstein</surname><given-names>C.</given-names></name>
<name><surname>Husain</surname><given-names>S.</given-names></name>
<name><surname>Lilly</surname><given-names>L.</given-names></name>
<name><surname>Renner</surname><given-names>E.</given-names></name>
<name><surname>Mazzulli</surname><given-names>T.</given-names></name>
</person-group><article-title>Hepatitis C core Ag and its clinical applicability: Potential advantages and disadvantages for diagnosis and follow-up?</article-title><source>Rev. Med. Virol.</source><year>2012</year><volume>22</volume><fpage>156</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1002/rmv.717</pub-id><pub-id pub-id-type="pmid">22121001</pub-id>
</element-citation></ref><ref id="B39-viruses-16-01863"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Jie</surname><given-names>W.</given-names></name>
<name><surname>Ling</surname><given-names>J.</given-names></name>
<name><surname>Yuanshuai</surname><given-names>H.</given-names></name>
</person-group><article-title>HCV core antigen plays an important role in the fight against HCV as an alternative to HCV-RNA detection</article-title><source>J. Clin. Lab. Anal.</source><year>2021</year><volume>35</volume><fpage>e23755</fpage><pub-id pub-id-type="doi">10.1002/jcla.23755</pub-id><pub-id pub-id-type="pmid">33788295</pub-id>
</element-citation></ref><ref id="B40-viruses-16-01863"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adland</surname><given-names>E.</given-names></name>
<name><surname>Jesuthasan</surname><given-names>G.</given-names></name>
<name><surname>Downs</surname><given-names>L.</given-names></name>
<name><surname>Wharton</surname><given-names>V.</given-names></name>
<name><surname>Wilde</surname><given-names>G.</given-names></name>
<name><surname>McNaughton</surname><given-names>A.L.</given-names></name>
<name><surname>Collier</surname><given-names>J.</given-names></name>
<name><surname>Barnes</surname><given-names>E.</given-names></name>
<name><surname>Klenerman</surname><given-names>P.</given-names></name>
<name><surname>Andersson</surname><given-names>M.</given-names></name>
</person-group><article-title>Hepatitis virus (HCV) diagnosis and access to treatment in a UK cohort</article-title><source>BMC Infect. Dis.</source><year>2018</year><volume>18</volume><fpage>461</fpage><pub-id pub-id-type="doi">10.1186/s12879-018-3367-3</pub-id><pub-id pub-id-type="pmid">30217169</pub-id>
</element-citation></ref><ref id="B41-viruses-16-01863"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Medici</surname><given-names>M.C.</given-names></name>
<name><surname>Chezzi</surname><given-names>C.</given-names></name>
<name><surname>De Conto</surname><given-names>F.</given-names></name>
<name><surname>Ferraglia</surname><given-names>F.</given-names></name>
<name><surname>Pinardi</surname><given-names>F.</given-names></name>
<name><surname>Arcangeletti</surname><given-names>M.C.</given-names></name>
<name><surname>Bernasconi</surname><given-names>D.</given-names></name>
<name><surname>Galli</surname><given-names>C.</given-names></name>
<name><surname>Calderaro</surname><given-names>A.</given-names></name>
</person-group><article-title>Evolving strategy for HCV testing in an Italian tertiary care hospital</article-title><source>J. Clin. Virol.</source><year>2016</year><volume>77</volume><fpage>92</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2016.02.017</pub-id><pub-id pub-id-type="pmid">26921741</pub-id>
</element-citation></ref><ref id="B42-viruses-16-01863"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>P&#x000e9;rez-Garc&#x000ed;a</surname><given-names>A.</given-names></name>
<name><surname>Aguinaga</surname><given-names>A.</given-names></name>
<name><surname>Navascu&#x000e9;s</surname><given-names>A.</given-names></name>
<name><surname>Castilla</surname><given-names>J.</given-names></name>
<name><surname>Ezpeleta</surname><given-names>C.</given-names></name>
</person-group><article-title>Hepatitis C core antigen: Diagnosis and monitoring of patients infected with hepatitis C virus</article-title><source>Int. J. Infect. Dis.</source><year>2019</year><volume>89</volume><fpage>131</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2019.09.022</pub-id><pub-id pub-id-type="pmid">31580940</pub-id>
</element-citation></ref><ref id="B43-viruses-16-01863"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Suttichaimongkol</surname><given-names>T.</given-names></name>
<name><surname>Saikong</surname><given-names>W.</given-names></name>
<name><surname>Sukeepaisarnjaroen</surname><given-names>W.</given-names></name>
</person-group><article-title>Diagnostic performance and correlation of hepatitis C virus core antigen compared with hepatitis C virus RNA</article-title><source>J. Med. Assoc. Thail.</source><year>2019</year><volume>102</volume><fpage>75</fpage><lpage>80</lpage></element-citation></ref><ref id="B44-viruses-16-01863"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wong</surname><given-names>X.Z.</given-names></name>
<name><surname>Gan</surname><given-names>C.C.</given-names></name>
<name><surname>Mohamed</surname><given-names>R.</given-names></name>
<name><surname>Yahya</surname><given-names>R.</given-names></name>
<name><surname>Ganapathy</surname><given-names>S.</given-names></name>
<name><surname>Tan</surname><given-names>S.S.</given-names></name>
<name><surname>Lim</surname><given-names>S.K.</given-names></name>
</person-group><article-title>Hepatitis C core antigen testing to diagnose active hepatitis C infection among haemodialysis patients</article-title><source>BMC Nephrol.</source><year>2020</year><volume>21</volume><fpage>480</fpage><pub-id pub-id-type="doi">10.1186/s12882-020-02154-4</pub-id><pub-id pub-id-type="pmid">33187498</pub-id>
</element-citation></ref><ref id="B45-viruses-16-01863"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kallala</surname><given-names>O.</given-names></name>
<name><surname>Kacem</surname><given-names>S.</given-names></name>
<name><surname>Fodha</surname><given-names>I.</given-names></name>
<name><surname>Pozzetto</surname><given-names>B.</given-names></name>
<name><surname>Abdelhalim</surname><given-names>T.</given-names></name>
</person-group><article-title>Role of hepatitis C virus core antigen assay in hepatitis C care in developing country</article-title><source>Egypt. Liver J.</source><year>2021</year><volume>11</volume><fpage>77</fpage><pub-id pub-id-type="doi">10.1186/s43066-021-00146-z</pub-id><pub-id pub-id-type="pmid">34777874</pub-id>
</element-citation></ref><ref id="B46-viruses-16-01863"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heidrich</surname><given-names>B.</given-names></name>
<name><surname>Pischke</surname><given-names>S.</given-names></name>
<name><surname>Helfritz</surname><given-names>F.</given-names></name>
<name><surname>Mederacke</surname><given-names>I.</given-names></name>
<name><surname>Kirschner</surname><given-names>J.</given-names></name>
<name><surname>Schneider</surname><given-names>J.</given-names></name>
<name><surname>Raupach</surname><given-names>R.</given-names></name>
<name><surname>J&#x000e4;ckel</surname><given-names>E.</given-names></name>
<name><surname>Barg-Hock</surname><given-names>H.</given-names></name>
<name><surname>Lehner</surname><given-names>F.</given-names></name>
</person-group><article-title>Hepatitis C virus core antigen testing in liver and kidney transplant recipients</article-title><source>J. Viral Hepat.</source><year>2014</year><volume>21</volume><fpage>769</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1111/jvh.12204</pub-id><pub-id pub-id-type="pmid">24251818</pub-id>
</element-citation></ref><ref id="B47-viruses-16-01863"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chuaypen</surname><given-names>N.</given-names></name>
<name><surname>Khlaiphuengsin</surname><given-names>A.</given-names></name>
<name><surname>Prasoppokakorn</surname><given-names>T.</given-names></name>
<name><surname>Susantitaphong</surname><given-names>P.</given-names></name>
<name><surname>Prasithsirikul</surname><given-names>W.</given-names></name>
<name><surname>Avihingsanon</surname><given-names>A.</given-names></name>
<name><surname>Tangkijvanich</surname><given-names>P.</given-names></name>
<name><surname>Praditpornsilpa</surname><given-names>K.</given-names></name>
</person-group><article-title>Prevalence and genotype distribution of hepatitis C virus within hemodialysis units in Thailand: Role of HCV core antigen in the assessment of viremia</article-title><source>BMC Infect. Dis.</source><year>2022</year><volume>22</volume><fpage>79</fpage><pub-id pub-id-type="doi">10.1186/s12879-022-07074-2</pub-id><pub-id pub-id-type="pmid">35065604</pub-id>
</element-citation></ref><ref id="B48-viruses-16-01863"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Duchesne</surname><given-names>L.</given-names></name>
<name><surname>Njouom</surname><given-names>R.</given-names></name>
<name><surname>Lissock</surname><given-names>F.</given-names></name>
<name><surname>Tamko-Mella</surname><given-names>G.F.</given-names></name>
<name><surname>Rallier</surname><given-names>S.</given-names></name>
<name><surname>Poiteau</surname><given-names>L.</given-names></name>
<name><surname>Soulier</surname><given-names>A.</given-names></name>
<name><surname>Chevaliez</surname><given-names>S.</given-names></name>
<name><surname>Vernet</surname><given-names>G.</given-names></name>
<name><surname>Rouveau</surname><given-names>N.</given-names></name>
</person-group><article-title>HCV Ag quantification as a one-step procedure in diagnosing chronic hepatitis C infection in Cameroon: The ANRS 12336 study</article-title><source>J. Int. AIDS Soc.</source><year>2017</year><volume>20</volume><fpage>21446</fpage><pub-id pub-id-type="doi">10.7448/IAS.20.1.21446</pub-id><pub-id pub-id-type="pmid">28530032</pub-id>
</element-citation></ref><ref id="B49-viruses-16-01863"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hullegie</surname><given-names>S.J.</given-names></name>
<name><surname>GeurtsvanKessel</surname><given-names>C.H.</given-names></name>
<name><surname>van der Eijk</surname><given-names>A.A.</given-names></name>
<name><surname>Ramakers</surname><given-names>C.</given-names></name>
<name><surname>Rijnders</surname><given-names>B.J.</given-names></name>
</person-group><article-title>HCV antigen instead of RNA testing to diagnose acute HCV in patients treated in the Dutch Acute HCV in HIV Study</article-title><source>J. Int. AIDS Soc.</source><year>2017</year><volume>20</volume><fpage>21621</fpage><pub-id pub-id-type="doi">10.7448/IAS.20.1.21621</pub-id><pub-id pub-id-type="pmid">28692208</pub-id>
</element-citation></ref><ref id="B50-viruses-16-01863"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Catlett</surname><given-names>B.</given-names></name>
<name><surname>Lamoury</surname><given-names>F.M.J.</given-names></name>
<name><surname>Bajis</surname><given-names>S.</given-names></name>
<name><surname>Hajarizadeh</surname><given-names>B.</given-names></name>
<name><surname>Martinez</surname><given-names>D.</given-names></name>
<name><surname>Mowat</surname><given-names>Y.</given-names></name>
<name><surname>Cunningham</surname><given-names>P.H.</given-names></name>
<name><surname>Jacka</surname><given-names>B.P.</given-names></name>
<name><surname>Cloherty</surname><given-names>G.A.</given-names></name>
<name><surname>Marks</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study</article-title><source>J. Viral Hepat.</source><year>2019</year><volume>26</volume><fpage>1423</fpage><lpage>1430</lpage><pub-id pub-id-type="doi">10.1111/jvh.13196</pub-id><pub-id pub-id-type="pmid">31448470</pub-id>
</element-citation></ref><ref id="B51-viruses-16-01863"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lamoury</surname><given-names>F.M.</given-names></name>
<name><surname>Hajarizadeh</surname><given-names>B.</given-names></name>
<name><surname>Soker</surname><given-names>A.</given-names></name>
<name><surname>Martinez</surname><given-names>D.</given-names></name>
<name><surname>Quek</surname><given-names>C.</given-names></name>
<name><surname>Cunningham</surname><given-names>P.</given-names></name>
<name><surname>Catlett</surname><given-names>B.</given-names></name>
<name><surname>Cloherty</surname><given-names>G.</given-names></name>
<name><surname>Marks</surname><given-names>P.</given-names></name>
<name><surname>Amin</surname><given-names>J.</given-names></name>
</person-group><article-title>Evaluation of a hepatitis C virus core antigen assay in plasma and dried blood spot samples</article-title><source>J. Mol. Diagn.</source><year>2018</year><volume>20</volume><fpage>621</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1016/j.jmoldx.2018.05.010</pub-id><pub-id pub-id-type="pmid">29959023</pub-id>
</element-citation></ref><ref id="B52-viruses-16-01863"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Troyano-Hern&#x000e1;ez</surname><given-names>P.</given-names></name>
<name><surname>Herrador</surname><given-names>P.</given-names></name>
<name><surname>Gea</surname><given-names>F.</given-names></name>
<name><surname>Romero-Hern&#x000e1;ndez</surname><given-names>B.</given-names></name>
<name><surname>Reina</surname><given-names>G.</given-names></name>
<name><surname>Albillos</surname><given-names>A.</given-names></name>
<name><surname>Gal&#x000e1;n</surname><given-names>J.C.</given-names></name>
<name><surname>Holgu&#x000ed;n</surname><given-names>&#x000c1;.</given-names></name>
</person-group><article-title>Impact of storage time in dried blood samples (DBS) and dried plasma samples (DPS) for point-of-care hepatitis C virus (HCV) RNA quantification and HCV core antigen detection</article-title><source>Microbiol. Spectr.</source><year>2023</year><volume>11</volume><fpage>e01748-23</fpage><pub-id pub-id-type="doi">10.1128/spectrum.01748-23</pub-id><pub-id pub-id-type="pmid">37655908</pub-id>
</element-citation></ref><ref id="B53-viruses-16-01863"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miedouge</surname><given-names>M.</given-names></name>
<name><surname>Saune</surname><given-names>K.</given-names></name>
<name><surname>Kamar</surname><given-names>N.</given-names></name>
<name><surname>Rieu</surname><given-names>M.</given-names></name>
<name><surname>Rostaing</surname><given-names>L.</given-names></name>
<name><surname>Izopet</surname><given-names>J.</given-names></name>
</person-group><article-title>Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients</article-title><source>J. Clin. Virol.</source><year>2010</year><volume>48</volume><fpage>18</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2010.02.012</pub-id><pub-id pub-id-type="pmid">20233674</pub-id>
</element-citation></ref><ref id="B54-viruses-16-01863"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>Y.</given-names></name>
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
<name><surname>Kim</surname><given-names>B.S.</given-names></name>
<name><surname>Kim</surname><given-names>D.Y.</given-names></name>
<name><surname>Han</surname><given-names>K.H.</given-names></name>
<name><surname>Kim</surname><given-names>H.S.</given-names></name>
</person-group><article-title>New automated hepatitis C virus (HCV) core antigen assay as an alternative to real-time PCR for HCV RNA quantification</article-title><source>J. Clin. Microbiol.</source><year>2010</year><volume>48</volume><fpage>2253</fpage><lpage>2256</lpage><pub-id pub-id-type="doi">10.1128/JCM.01856-09</pub-id><pub-id pub-id-type="pmid">20351215</pub-id>
</element-citation></ref><ref id="B55-viruses-16-01863"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Erg&#x000fc;nay</surname><given-names>K.</given-names></name>
<name><surname>&#x0015e;ener</surname><given-names>B.</given-names></name>
<name><surname>Alp</surname><given-names>A.</given-names></name>
<name><surname>Karakaya</surname><given-names>J.</given-names></name>
<name><surname>Has&#x000e7;elik</surname><given-names>G.</given-names></name>
</person-group><article-title>Utility of a commercial quantitative hepatitis C virus core antigen assay in a diagnostic laboratory setting</article-title><source>Diagn. Microbiol. Infect. Dis.</source><year>2011</year><volume>70</volume><fpage>486</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2011.04.011</pub-id><pub-id pub-id-type="pmid">21767705</pub-id>
</element-citation></ref><ref id="B56-viruses-16-01863"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kesli</surname><given-names>R.</given-names></name>
<name><surname>Polat</surname><given-names>H.</given-names></name>
<name><surname>Terzi</surname><given-names>Y.</given-names></name>
<name><surname>Kurtoglu</surname><given-names>M.G.</given-names></name>
<name><surname>Uyar</surname><given-names>Y.</given-names></name>
</person-group><article-title>Comparison of a newly developed automated and quantitative hepatitis C virus (HCV) core antigen test with the HCV RNA assay for clinical usefulness in confirming anti-HCV results</article-title><source>J. Clin. Microbiol.</source><year>2011</year><volume>49</volume><fpage>4089</fpage><lpage>4093</lpage><pub-id pub-id-type="doi">10.1128/JCM.05292-11</pub-id><pub-id pub-id-type="pmid">21940466</pub-id>
</element-citation></ref><ref id="B57-viruses-16-01863"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kuo</surname><given-names>Y.-H.</given-names></name>
<name><surname>Chang</surname><given-names>K.-C.</given-names></name>
<name><surname>Wang</surname><given-names>J.-H.</given-names></name>
<name><surname>Tsai</surname><given-names>P.-S.</given-names></name>
<name><surname>Hung</surname><given-names>S.-F.</given-names></name>
<name><surname>Hung</surname><given-names>C.-H.</given-names></name>
<name><surname>Chen</surname><given-names>C.-H.</given-names></name>
<name><surname>Lu</surname><given-names>S.-N.</given-names></name>
</person-group><article-title>Is hepatitis C virus core antigen an adequate marker for community screening?</article-title><source>J. Clin. Microbiol.</source><year>2012</year><volume>50</volume><fpage>1989</fpage><lpage>1993</lpage><pub-id pub-id-type="doi">10.1128/JCM.05175-11</pub-id><pub-id pub-id-type="pmid">22461676</pub-id>
</element-citation></ref><ref id="B58-viruses-16-01863"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alados-Arboledas</surname><given-names>J.C.</given-names></name>
<name><surname>L&#x000f3;pez-Prieto</surname><given-names>M.D.</given-names></name>
<name><surname>Lopez-Cepero</surname><given-names>J.</given-names></name>
</person-group><article-title>Role of the new Architect HCV Ag<sup>&#x000ae;</sup> assay in the management of hepatitis C na&#x000ef;ve patients</article-title><source>Enfermedades Infecc. Y Microbiol. Clin.</source><year>2012</year><volume>31</volume><fpage>351</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1016/j.eimc.2012.09.014</pub-id><pub-id pub-id-type="pmid">23182239</pub-id>
</element-citation></ref><ref id="B59-viruses-16-01863"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hadziyannis</surname><given-names>E.</given-names></name>
<name><surname>Minopetrou</surname><given-names>M.</given-names></name>
<name><surname>Georgiou</surname><given-names>A.</given-names></name>
<name><surname>Spanou</surname><given-names>F.</given-names></name>
<name><surname>Koskinas</surname><given-names>J.</given-names></name>
</person-group><article-title>Is HCV core antigen a reliable marker of viral load? An evaluation of HCV core antigen automated immunoassay</article-title><source>Ann. Gastroenterol.</source><year>2013</year><volume>26</volume><fpage>146</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">24714621</pub-id>
</element-citation></ref><ref id="B60-viruses-16-01863"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Buket</surname><given-names>C.A.</given-names></name>
<name><surname>Ay&#x0015f;e</surname><given-names>A.</given-names></name>
<name><surname>Sel&#x000e7;uk</surname><given-names>K.</given-names></name>
<name><surname>S&#x000fc;leyman</surname><given-names>&#x000d6;.</given-names></name>
<name><surname>Emel</surname><given-names>S.&#x000c7;.</given-names></name>
</person-group><article-title>Comparison of HCV core antigen and anti-HCV with HCV RNA results</article-title><source>Afr. Health Sci.</source><year>2014</year><volume>14</volume><fpage>816</fpage><lpage>820</lpage><pub-id pub-id-type="doi">10.4314/ahs.v14i4.7</pub-id><pub-id pub-id-type="pmid">25834488</pub-id>
</element-citation></ref><ref id="B61-viruses-16-01863"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chevaliez</surname><given-names>S.</given-names></name>
<name><surname>Soulier</surname><given-names>A.</given-names></name>
<name><surname>Poiteau</surname><given-names>L.</given-names></name>
<name><surname>Bouvier-Alias</surname><given-names>M.</given-names></name>
<name><surname>Pawlotsky</surname><given-names>J.-M.</given-names></name>
</person-group><article-title>Clinical utility of hepatitis C virus core antigen quantification in patients with chronic hepatitis C</article-title><source>J. Clin. Virol.</source><year>2014</year><volume>61</volume><fpage>145</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2014.05.014</pub-id><pub-id pub-id-type="pmid">24973282</pub-id>
</element-citation></ref><ref id="B62-viruses-16-01863"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Florea</surname><given-names>D.</given-names></name>
<name><surname>Neaga</surname><given-names>E.</given-names></name>
<name><surname>Nicolae</surname><given-names>I.</given-names></name>
<name><surname>Maxim</surname><given-names>D.</given-names></name>
<name><surname>Popa</surname><given-names>M.</given-names></name>
<name><surname>Otelea</surname><given-names>D.</given-names></name>
</person-group><article-title>Clinical usefulness of HCV core antigen assay for the management of patients with chronic hepatitis C</article-title><source>J. Gastrointest. Liver Dis.</source><year>2014</year><volume>23</volume><fpage>393</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.15403/jgld.2014.1121.234.chcv</pub-id></element-citation></ref><ref id="B63-viruses-16-01863"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garbuglia</surname><given-names>A.R.</given-names></name>
<name><surname>Monachetti</surname><given-names>A.</given-names></name>
<name><surname>Galli</surname><given-names>C.</given-names></name>
<name><surname>Sabatini</surname><given-names>R.</given-names></name>
<name><surname>Ferreri</surname><given-names>M.L.</given-names></name>
<name><surname>Capobianchi</surname><given-names>M.R.</given-names></name>
<name><surname>Bagnarelli</surname><given-names>P.</given-names></name>
</person-group><article-title>HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes</article-title><source>BMC Infect. Dis.</source><year>2014</year><volume>14</volume><fpage>222</fpage><pub-id pub-id-type="doi">10.1186/1471-2334-14-222</pub-id><pub-id pub-id-type="pmid">24758157</pub-id>
</element-citation></ref><ref id="B64-viruses-16-01863"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kadkhoda</surname><given-names>K.</given-names></name>
<name><surname>Smart</surname><given-names>G.</given-names></name>
</person-group><article-title>HCV antigen testing for the diagnosis of hepatitis C infection: A cost-efficient algorithm</article-title><source>Clin. Lab.</source><year>2014</year><volume>60</volume><fpage>677</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.7754/Clin.Lab.2013.130634</pub-id><pub-id pub-id-type="pmid">24779304</pub-id>
</element-citation></ref><ref id="B65-viruses-16-01863"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reyes-M&#x000e9;ndez</surname><given-names>M.&#x000c1;.</given-names></name>
<name><surname>Ju&#x000e1;rez-Figueroa</surname><given-names>L.</given-names></name>
<name><surname>Iracheta-Hern&#x000e1;ndez</surname><given-names>P.</given-names></name>
<name><surname>Medina-Islas</surname><given-names>Y.</given-names></name>
<name><surname>Ruiz-Gonz&#x000e1;lez</surname><given-names>V.</given-names></name>
</person-group><article-title>Comparison of two diagnostic algorithms for the identification of patients with HCV viremia using a new HCV antigen test</article-title><source>Ann. Hepatol.</source><year>2014</year><volume>13</volume><fpage>337</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1016/S1665-2681(19)30862-2</pub-id><pub-id pub-id-type="pmid">24756008</pub-id>
</element-citation></ref><ref id="B66-viruses-16-01863"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>van Helden</surname><given-names>J.</given-names></name>
<name><surname>Weiskirchen</surname><given-names>R.</given-names></name>
</person-group><article-title>Hepatitis C diagnostics: Clinical evaluation of the HCV-core antigen determination</article-title><source>Z Gastroenterol.</source><year>2014</year><volume>52</volume><fpage>1164</fpage><lpage>1170</lpage><pub-id pub-id-type="pmid">25313628</pub-id>
</element-citation></ref><ref id="B67-viruses-16-01863"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kamal</surname><given-names>S.</given-names></name>
<name><surname>Kassim</surname><given-names>S.</given-names></name>
<name><surname>El Gohary</surname><given-names>E.</given-names></name>
<name><surname>Fouad</surname><given-names>A.</given-names></name>
<name><surname>Nabegh</surname><given-names>L.</given-names></name>
<name><surname>Hafez</surname><given-names>T.</given-names></name>
<name><surname>Bahnasy</surname><given-names>K.</given-names></name>
<name><surname>Hassan</surname><given-names>H.</given-names></name>
<name><surname>Ghoraba</surname><given-names>D.</given-names></name>
</person-group><article-title>The accuracy and cost-effectiveness of hepatitis C core antigen assay in the monitoring of anti-viral therapy in patients with chronic hepatitis C genotype 4</article-title><source>Aliment. Pharmacol. Ther.</source><year>2015</year><volume>42</volume><fpage>307</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1111/apt.13261</pub-id><pub-id pub-id-type="pmid">26018116</pub-id>
</element-citation></ref><ref id="B68-viruses-16-01863"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feyzio&#x0011f;lu</surname><given-names>B.</given-names></name>
<name><surname>Baysal</surname><given-names>B.</given-names></name>
<name><surname>Demircili</surname><given-names>M.E.</given-names></name>
<name><surname>&#x000d6;zdemir</surname><given-names>M.</given-names></name>
</person-group><article-title>The Efficiency of Hepatitis C Virus Core Antigen Test in the Diagnosis of Hepatitis C Infection</article-title><source>J. Viral Hepat.</source><year>2016</year><volume>1</volume><fpage>18</fpage><lpage>22</lpage></element-citation></ref><ref id="B69-viruses-16-01863"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alonso</surname><given-names>R.</given-names></name>
<name><surname>P&#x000e9;rez-Garc&#x000ed;a</surname><given-names>F.</given-names></name>
<name><surname>Ampuero</surname><given-names>D.</given-names></name>
<name><surname>Reigadas</surname><given-names>E.</given-names></name>
<name><surname>Bouza</surname><given-names>E.</given-names></name>
</person-group><article-title>New direct-acting antivirals for patients with chronic HCV infection: Can we monitor treatment using an HCV core antigen assay?</article-title><source>Diagn. Microbiol. Infect. Dis.</source><year>2017</year><volume>87</volume><fpage>243</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2016.11.010</pub-id><pub-id pub-id-type="pmid">27916546</pub-id>
</element-citation></ref><ref id="B70-viruses-16-01863"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>&#x000c7;etiner</surname><given-names>S.</given-names></name>
<name><surname>Duran</surname><given-names>A.&#x000c7;.</given-names></name>
<name><surname>Kibar</surname><given-names>F.</given-names></name>
<name><surname>Yaman</surname><given-names>A.</given-names></name>
</person-group><article-title>Performance comparison of new generation HCV core antigen test versus HCV RNA test in management of hepatitis C virus infection</article-title><source>Transfus. Apher. Sci.</source><year>2017</year><volume>56</volume><fpage>362</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1016/j.transci.2017.02.005</pub-id><pub-id pub-id-type="pmid">28342642</pub-id>
</element-citation></ref><ref id="B71-viruses-16-01863"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mohamed</surname><given-names>Z.</given-names></name>
<name><surname>Mbwambo</surname><given-names>J.</given-names></name>
<name><surname>Shimakawa</surname><given-names>Y.</given-names></name>
<name><surname>Poiteau</surname><given-names>L.</given-names></name>
<name><surname>Chevaliez</surname><given-names>S.</given-names></name>
<name><surname>Pawlotsky</surname><given-names>J.M.</given-names></name>
<name><surname>Rwegasha</surname><given-names>J.</given-names></name>
<name><surname>Bhagani</surname><given-names>S.</given-names></name>
<name><surname>Taylor-Robinson</surname><given-names>S.D.</given-names></name>
<name><surname>Makani</surname><given-names>J.</given-names></name>
</person-group><article-title>Clinical utility of HCV core antigen detection and quantification using serum samples and dried blood spots in people who inject drugs in Dar-es-Salaam, Tanzania</article-title><source>J. Int. AIDS Soc.</source><year>2017</year><volume>20</volume><fpage>21856</fpage><pub-id pub-id-type="doi">10.7448/IAS.20.1.21856</pub-id><pub-id pub-id-type="pmid">28953324</pub-id>
</element-citation></ref><ref id="B72-viruses-16-01863"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rockstroh</surname><given-names>J.K.</given-names></name>
<name><surname>Feld</surname><given-names>J.J.</given-names></name>
<name><surname>Chevaliez</surname><given-names>S.</given-names></name>
<name><surname>Cheng</surname><given-names>K.</given-names></name>
<name><surname>Wedemeyer</surname><given-names>H.</given-names></name>
<name><surname>Sarrazin</surname><given-names>C.</given-names></name>
<name><surname>Maasoumy</surname><given-names>B.</given-names></name>
<name><surname>Herman</surname><given-names>C.</given-names></name>
<name><surname>Hackett</surname><given-names>J.</given-names><suffix>Jr.</suffix></name>
<name><surname>Cohen</surname><given-names>D.E.</given-names></name>
</person-group><article-title>HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients</article-title><source>J. Virol. Methods</source><year>2017</year><volume>245</volume><fpage>14</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2017.03.002</pub-id><pub-id pub-id-type="pmid">28359920</pub-id>
</element-citation></ref><ref id="B73-viruses-16-01863"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Talal</surname><given-names>A.H.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Zeremski</surname><given-names>M.</given-names></name>
<name><surname>Zavala</surname><given-names>R.</given-names></name>
<name><surname>Sylvester</surname><given-names>C.</given-names></name>
<name><surname>Kuhns</surname><given-names>M.</given-names></name>
<name><surname>Brown</surname><given-names>L.S.</given-names></name>
<name><surname>Markatou</surname><given-names>M.</given-names></name>
<name><surname>Cloherty</surname><given-names>G.A.</given-names></name>
</person-group><article-title>Hepatitis C virus core antigen: A potential alternative to HCV RNA testing among persons with substance use disorders</article-title><source>J. Subst. Abus. Treat.</source><year>2017</year><volume>78</volume><fpage>37</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.jsat.2017.04.011</pub-id></element-citation></ref><ref id="B74-viruses-16-01863"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wasitthankasem</surname><given-names>R.</given-names></name>
<name><surname>Vichaiwattana</surname><given-names>P.</given-names></name>
<name><surname>Auphimai</surname><given-names>C.</given-names></name>
<name><surname>Siripon</surname><given-names>N.</given-names></name>
<name><surname>Klinfueng</surname><given-names>S.</given-names></name>
<name><surname>Tangkijvanich</surname><given-names>P.</given-names></name>
<name><surname>Vongpunsawad</surname><given-names>S.</given-names></name>
<name><surname>Poovorawan</surname><given-names>Y.</given-names></name>
</person-group><article-title>HCV core antigen is an alternative marker to HCV RNA for evaluating active HCV infection: Implications for improved diagnostic option in an era of affordable DAAs</article-title><source>PeerJ</source><year>2017</year><volume>5</volume><fpage>e4008</fpage><pub-id pub-id-type="doi">10.7717/peerj.4008</pub-id><pub-id pub-id-type="pmid">29134150</pub-id>
</element-citation></ref><ref id="B75-viruses-16-01863"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alonso</surname><given-names>R.</given-names></name>
<name><surname>P&#x000e8;c</surname><given-names>F.</given-names></name>
<name><surname>L&#x000f3;pez-Roa</surname><given-names>P.</given-names></name>
<name><surname>Alcal&#x000e1;</surname><given-names>L.</given-names></name>
<name><surname>Rode&#x000f1;o</surname><given-names>P.</given-names></name>
<name><surname>Bouza</surname><given-names>E.</given-names></name>
</person-group><article-title>HCV core-antigen assay as an alternative to HCV RNA quantification: A correlation study for the assessment of HCV viremia</article-title><source>Enfermedades Infecc. Y Microbiol. Clin.</source><year>2018</year><volume>36</volume><fpage>175</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1016/j.eimc.2016.11.013</pub-id></element-citation></ref><ref id="B76-viruses-16-01863"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Benito</surname><given-names>R.</given-names></name>
<name><surname>Arribas</surname><given-names>J.</given-names></name>
<name><surname>Algarate</surname><given-names>S.</given-names></name>
<name><surname>Cebollada</surname><given-names>R.</given-names></name>
<name><surname>Gude</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Hepatitis C virus core antigen for screening organ donors and recipients</article-title><source>Diagn. Microbiol. Infect. Dis.</source><year>2018</year><volume>91</volume><fpage>126</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2018.01.021</pub-id><pub-id pub-id-type="pmid">29477273</pub-id>
</element-citation></ref><ref id="B77-viruses-16-01863"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chang</surname><given-names>C.</given-names></name>
<name><surname>Hung</surname><given-names>C.-H.</given-names></name>
<name><surname>Wang</surname><given-names>J.-H.</given-names></name>
<name><surname>Lu</surname><given-names>S.-N.</given-names></name>
</person-group><article-title>Hepatitis C core antigen highly correlated to HCV RNA</article-title><source>Kaohsiung J. Med. Sci.</source><year>2018</year><volume>34</volume><fpage>684</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.1016/j.kjms.2018.08.002</pub-id><pub-id pub-id-type="pmid">30527202</pub-id>
</element-citation></ref><ref id="B78-viruses-16-01863"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kyuregyan</surname><given-names>K.K.</given-names></name>
<name><surname>Malinnikova</surname><given-names>E.Y.</given-names></name>
<name><surname>Soboleva</surname><given-names>N.V.</given-names></name>
<name><surname>Isaeva</surname><given-names>O.V.</given-names></name>
<name><surname>Karlsen</surname><given-names>A.A.</given-names></name>
<name><surname>Kichatova</surname><given-names>V.S.</given-names></name>
<name><surname>Potemkin</surname><given-names>I.A.</given-names></name>
<name><surname>Schibrik</surname><given-names>E.V.</given-names></name>
<name><surname>Gadjieva</surname><given-names>O.A.</given-names></name>
<name><surname>Bashiryan</surname><given-names>B.A.</given-names></name>
</person-group><article-title>Community screening for hepatitis C virus infection in a low-prevalence population</article-title><source>BMC Public Health</source><year>2019</year><volume>19</volume><fpage>1038</fpage><pub-id pub-id-type="doi">10.1186/s12889-019-7388-7</pub-id><pub-id pub-id-type="pmid">31375104</pub-id>
</element-citation></ref><ref id="B79-viruses-16-01863"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiang</surname><given-names>Y.</given-names></name>
<name><surname>Lai</surname><given-names>X.F.</given-names></name>
<name><surname>Chen</surname><given-names>P.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
</person-group><article-title>The correlation of HCV RNA and HCV core antigen in different genotypes of HCV</article-title><source>J. Clin. Lab. Anal.</source><year>2019</year><volume>33</volume><fpage>e22632</fpage><pub-id pub-id-type="doi">10.1002/jcla.22632</pub-id><pub-id pub-id-type="pmid">30069909</pub-id>
</element-citation></ref><ref id="B80-viruses-16-01863"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pollock</surname><given-names>K.G.</given-names></name>
<name><surname>McDonald</surname><given-names>S.A.</given-names></name>
<name><surname>Gunson</surname><given-names>R.</given-names></name>
<name><surname>McLeod</surname><given-names>A.</given-names></name>
<name><surname>Went</surname><given-names>A.</given-names></name>
<name><surname>Goldberg</surname><given-names>D.J.</given-names></name>
<name><surname>Hutchinson</surname><given-names>S.J.</given-names></name>
<name><surname>Barclay</surname><given-names>S.T.</given-names></name>
</person-group><article-title>Real-world utility of HCV core antigen as an alternative to HCV RNA testing: Implications for viral load and genotype</article-title><source>J. Viral. Hepat.</source><year>2020</year><volume>27</volume><fpage>996</fpage><lpage>1002</lpage><pub-id pub-id-type="doi">10.1111/jvh.13337</pub-id><pub-id pub-id-type="pmid">32479681</pub-id>
</element-citation></ref><ref id="B81-viruses-16-01863"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abid</surname><given-names>A.</given-names></name>
<name><surname>Uddin</surname><given-names>M.</given-names></name>
<name><surname>Muhammad</surname><given-names>T.</given-names></name>
<name><surname>Awan</surname><given-names>S.</given-names></name>
<name><surname>Applegate</surname><given-names>T.</given-names></name>
<name><surname>Dore</surname><given-names>G.J.</given-names></name>
<name><surname>Cloherty</surname><given-names>G.</given-names></name>
<name><surname>Hamid</surname><given-names>S.</given-names></name>
</person-group><article-title>Evaluation of hepatitis C virus core antigen assay in a resource-limited setting in Pakistan</article-title><source>Diagnostics</source><year>2021</year><volume>11</volume><elocation-id>1354</elocation-id><pub-id pub-id-type="doi">10.3390/diagnostics11081354</pub-id><pub-id pub-id-type="pmid">34441289</pub-id>
</element-citation></ref><ref id="B82-viruses-16-01863"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>W.-M.</given-names></name>
<name><surname>Lee</surname><given-names>C.-Y.</given-names></name>
<name><surname>Hsu</surname><given-names>N.-T.</given-names></name>
<name><surname>Huang</surname><given-names>W.-C.</given-names></name>
<name><surname>Chen</surname><given-names>M.-Y.</given-names></name>
<name><surname>Huang</surname><given-names>T.-J.</given-names></name>
<name><surname>Lu</surname><given-names>S.-N.</given-names></name>
</person-group><article-title>Feasibility of anti-HCV reflex HCV Ag screening strategy in an HCV endemic community</article-title><source>J. Formos. Med. Assoc.</source><year>2021</year><volume>120</volume><fpage>1237</fpage><lpage>1241</lpage><pub-id pub-id-type="doi">10.1016/j.jfma.2020.09.013</pub-id><pub-id pub-id-type="pmid">33008696</pub-id>
</element-citation></ref><ref id="B83-viruses-16-01863"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kannan</surname><given-names>A.</given-names></name>
<name><surname>Biswas</surname><given-names>L.</given-names></name>
<name><surname>Kumar</surname><given-names>A.</given-names></name>
<name><surname>Kurian</surname><given-names>J.</given-names></name>
<name><surname>S Nair</surname><given-names>A.</given-names></name>
<name><surname>Suresh</surname><given-names>P.</given-names></name>
<name><surname>Sadasivan</surname><given-names>S.</given-names></name>
<name><surname>Biswas</surname><given-names>R.</given-names></name>
</person-group><article-title>Improving diagnosis of hepatitis C virus infection using hepatitis C core antigen testing in a resource-poor setting</article-title><source>Rev. Soc. Bras. Med. Trop.</source><year>2021</year><volume>54</volume><fpage>e02532020</fpage><pub-id pub-id-type="doi">10.1590/0037-8682-0253-2020</pub-id><pub-id pub-id-type="pmid">33605377</pub-id>
</element-citation></ref><ref id="B84-viruses-16-01863"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>R.</given-names></name>
<name><surname>Chan</surname><given-names>K.P.</given-names></name>
<name><surname>Ekstrom</surname><given-names>V.S.M.</given-names></name>
<name><surname>Wong</surname><given-names>J.C.C.</given-names></name>
<name><surname>Lim</surname><given-names>K.L.</given-names></name>
<name><surname>Ng</surname><given-names>W.C.</given-names></name>
<name><surname>Woo</surname><given-names>S.M.</given-names></name>
<name><surname>Chan</surname><given-names>K.S.</given-names></name>
<name><surname>Thangaraju</surname><given-names>S.</given-names></name>
<name><surname>Kee</surname><given-names>T.Y.S.</given-names></name>
</person-group><article-title>Hepatitis C virus antigen detection is an appropriate test for screening and early diagnosis of hepatitis C virus infection in at-risk populations and immunocompromised hosts</article-title><source>J. Med. Virol.</source><year>2021</year><volume>93</volume><fpage>3738</fpage><lpage>3743</lpage><pub-id pub-id-type="doi">10.1002/jmv.26433</pub-id><pub-id pub-id-type="pmid">32797627</pub-id>
</element-citation></ref><ref id="B85-viruses-16-01863"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumbhar</surname><given-names>N.</given-names></name>
<name><surname>Ramachandran</surname><given-names>K.</given-names></name>
<name><surname>Kumar</surname><given-names>G.</given-names></name>
<name><surname>Pasupuleti</surname><given-names>S.S.R.</given-names></name>
<name><surname>Sharma</surname><given-names>M.K.</given-names></name>
<name><surname>Gupta</surname><given-names>E.</given-names></name>
</person-group><article-title>Utility of hepatitis C virus core antigen testing for diagnosis and treatment monitoring in HCV infection: A study from India</article-title><source>Indian J. Med. Microbiol.</source><year>2021</year><volume>39</volume><fpage>462</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1016/j.ijmmb.2021.07.002</pub-id><pub-id pub-id-type="pmid">34294505</pub-id>
</element-citation></ref><ref id="B86-viruses-16-01863"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ponnuvel</surname><given-names>S.</given-names></name>
<name><surname>Fletcher</surname><given-names>G.J.</given-names></name>
<name><surname>Anantharam</surname><given-names>R.</given-names></name>
<name><surname>Varughese</surname><given-names>S.</given-names></name>
<name><surname>David</surname><given-names>V.G.</given-names></name>
<name><surname>Abraham</surname><given-names>P.</given-names></name>
</person-group><article-title>Clinical utility of hepatitis C virus core antigen (HCVcAg) assay to identify active HCV infection in hemodialysis and renal transplant patients</article-title><source>PLoS ONE</source><year>2021</year><volume>16</volume><fpage>e0250263</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0250263</pub-id><pub-id pub-id-type="pmid">33886631</pub-id>
</element-citation></ref><ref id="B87-viruses-16-01863"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Le</surname><given-names>T.T.N.</given-names></name>
<name><surname>Tran</surname><given-names>V.L.</given-names></name>
<name><surname>Luong</surname><given-names>T.T.D.</given-names></name>
<name><surname>Ngo</surname><given-names>Q.D.</given-names></name>
<name><surname>Nguyen</surname><given-names>M.H.</given-names></name>
</person-group><article-title>Value of HCV core antigen test in screening for Hepatitis C virus</article-title><source>Vietnam. Med. J.</source><year>2022</year><volume>516</volume><fpage>254</fpage><lpage>257</lpage></element-citation></ref><ref id="B88-viruses-16-01863"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>H.-Y.</given-names></name>
<name><surname>Liu</surname><given-names>W.-D.</given-names></name>
<name><surname>Wang</surname><given-names>C.-W.</given-names></name>
<name><surname>Wei</surname><given-names>Y.-J.</given-names></name>
<name><surname>Lin</surname><given-names>K.-Y.</given-names></name>
<name><surname>Huang</surname><given-names>Y.-S.</given-names></name>
<name><surname>Su</surname><given-names>L.-H.</given-names></name>
<name><surname>Chen</surname><given-names>Y.-T.</given-names></name>
<name><surname>Liu</surname><given-names>W.-C.</given-names></name>
<name><surname>Su</surname><given-names>Y.-C.</given-names></name>
</person-group><article-title>Performance of hepatitis C virus (HCV) core antigen assay in the diagnosis of recently acquired HCV infection among high-risk populations</article-title><source>Microbiol. Spectr.</source><year>2022</year><volume>10</volume><fpage>e00345-22</fpage><pub-id pub-id-type="doi">10.1128/spectrum.00345-22</pub-id><pub-id pub-id-type="pmid">35579445</pub-id>
</element-citation></ref><ref id="B89-viruses-16-01863"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ponnuvel</surname><given-names>S.</given-names></name>
<name><surname>Prakash</surname><given-names>A.</given-names></name>
<name><surname>Steve</surname><given-names>R.J.</given-names></name>
<name><surname>Doss</surname><given-names>G.P.</given-names></name>
<name><surname>Goel</surname><given-names>A.</given-names></name>
<name><surname>Zachariah</surname><given-names>U.G.</given-names></name>
<name><surname>Eapen</surname><given-names>C.E.</given-names></name>
<name><surname>Rebekah</surname><given-names>G.</given-names></name>
<name><surname>Kannangai</surname><given-names>R.</given-names></name>
<name><surname>Fletcher</surname><given-names>G.J.</given-names></name>
</person-group><article-title>Longitudinal assessment of HCV core antigen kinetics to monitor therapeutic response in the age of DAAs</article-title><source>PLoS ONE</source><year>2023</year><volume>18</volume><fpage>e0282013</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0282013</pub-id><pub-id pub-id-type="pmid">36800372</pub-id>
</element-citation></ref><ref id="B90-viruses-16-01863"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eid</surname><given-names>M.A.</given-names></name>
<name><surname>Melek</surname><given-names>S.T.</given-names></name>
<name><surname>Sharafeldin</surname><given-names>M.A.</given-names></name>
<name><surname>El-Shouny</surname><given-names>W.A.</given-names></name>
</person-group><article-title>Quantitative and Qualitative Evaluation of Hepatitis C Virus Core Antigen (HCVcAg) as an Alternative Diagnostic Marker in Chronic HCV Infection</article-title><source>Delta J. Sci.</source><year>2023</year><volume>46</volume><fpage>111</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.21608/djs.2023.217624.1119</pub-id></element-citation></ref><ref id="B91-viruses-16-01863"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vieira</surname><given-names>R.</given-names></name>
<name><surname>Caldas</surname><given-names>C.</given-names></name>
<name><surname>Carvalho</surname><given-names>J.A.</given-names></name>
<name><surname>Costa</surname><given-names>E.</given-names></name>
<name><surname>Magalhaes</surname><given-names>T.R.</given-names></name>
<name><surname>Queiroga</surname><given-names>F.L.</given-names></name>
</person-group><article-title>HCV Core-antigen Assay as an Effective Alternative to HCV RNA Quantification in Patients with Hepatitis C</article-title><source>In Vivo</source><year>2023</year><volume>37</volume><fpage>1498</fpage><lpage>1503</lpage><pub-id pub-id-type="doi">10.21873/invivo.13234</pub-id><pub-id pub-id-type="pmid">37369475</pub-id>
</element-citation></ref><ref id="B92-viruses-16-01863"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Naveed</surname><given-names>A.</given-names></name>
<name><surname>Khalid</surname><given-names>A.</given-names></name>
<name><surname>Janjua</surname><given-names>N.</given-names></name>
<name><surname>Cloherty</surname><given-names>G.A.</given-names></name>
<name><surname>Akhter</surname><given-names>S.</given-names></name>
</person-group><article-title>Performance of HCV core antigen and PCR testing in a predominantly genotype 3 population</article-title><source>J. Viral. Hepat.</source><year>2024</year><volume>31</volume><fpage>320</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1111/jvh.13937</pub-id><pub-id pub-id-type="pmid">38483043</pub-id>
</element-citation></ref><ref id="B93-viruses-16-01863"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garg</surname><given-names>J.</given-names></name>
<name><surname>Verma</surname><given-names>P.</given-names></name>
<name><surname>Singh</surname><given-names>M.</given-names></name>
<name><surname>Das</surname><given-names>A.</given-names></name>
<name><surname>Pathak</surname><given-names>A.</given-names></name>
<name><surname>Agarwal</surname><given-names>J.</given-names></name>
</person-group><article-title>Hepatitis C virus core antigen: A diagnostic and treatment monitoring marker of hepatitis C virus in Indian population</article-title><source>Indian J. Gastroenterol.</source><year>2024</year><volume>43</volume><fpage>799</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1007/s12664-024-01549-7</pub-id><pub-id pub-id-type="pmid">38619807</pub-id>
</element-citation></ref><ref id="B94-viruses-16-01863"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>S.F.</given-names></name>
<name><surname>Tung</surname><given-names>S.Y.</given-names></name>
<name><surname>Wei</surname><given-names>K.L.</given-names></name>
<name><surname>Chen</surname><given-names>C.H.</given-names></name>
<name><surname>Hu</surname><given-names>T.H.</given-names></name>
<name><surname>Shen</surname><given-names>C.H.</given-names></name>
<name><surname>Chang</surname><given-names>T.S.</given-names></name>
<name><surname>Chen</surname><given-names>W.M.</given-names></name>
<name><surname>Yen</surname><given-names>C.W.</given-names></name>
<name><surname>Wang</surname><given-names>J.H.</given-names></name>
<etal/>
</person-group><article-title>Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C</article-title><source>PLoS ONE</source><year>2020</year><volume>15</volume><fpage>e0229994</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0229994</pub-id><pub-id pub-id-type="pmid">32126125</pub-id>
</element-citation></ref><ref id="B95-viruses-16-01863"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nguyen</surname><given-names>L.T.</given-names></name>
<name><surname>Gray</surname><given-names>E.</given-names></name>
<name><surname>O&#x02019;Leary</surname><given-names>A.</given-names></name>
<name><surname>Carr</surname><given-names>M.</given-names></name>
<name><surname>De Gascun</surname><given-names>C.F.</given-names></name>
<name><surname>Network</surname><given-names>I.H.C.O.R.</given-names></name>
</person-group><article-title>The role of hepatitis C virus core antigen testing in the era of direct-acting antiviral therapies: What we can learn from the protease inhibitors</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><fpage>e0163900</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0163900</pub-id><pub-id pub-id-type="pmid">27711230</pub-id>
</element-citation></ref><ref id="B96-viruses-16-01863"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Loggi</surname><given-names>E.</given-names></name>
<name><surname>Galli</surname><given-names>S.</given-names></name>
<name><surname>Vitale</surname><given-names>G.</given-names></name>
<name><surname>Di Donato</surname><given-names>R.</given-names></name>
<name><surname>Vukotic</surname><given-names>R.</given-names></name>
<name><surname>Grandini</surname><given-names>E.</given-names></name>
<name><surname>Margotti</surname><given-names>M.</given-names></name>
<name><surname>Guarneri</surname><given-names>V.</given-names></name>
<name><surname>Furlini</surname><given-names>G.</given-names></name>
<name><surname>Galli</surname><given-names>C.</given-names></name>
</person-group><article-title>Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><fpage>e0187755</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0187755</pub-id><pub-id pub-id-type="pmid">29125869</pub-id>
</element-citation></ref><ref id="B97-viruses-16-01863"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rossetti</surname><given-names>B.</given-names></name>
<name><surname>Loggi</surname><given-names>E.</given-names></name>
<name><surname>Raffaelli</surname><given-names>C.S.</given-names></name>
<name><surname>Mercinelli</surname><given-names>S.</given-names></name>
<name><surname>Gandolfo</surname><given-names>C.</given-names></name>
<name><surname>Savellini</surname><given-names>G.G.</given-names></name>
<name><surname>Galli</surname><given-names>S.</given-names></name>
<name><surname>Vitale</surname><given-names>G.</given-names></name>
<name><surname>Di Donato</surname><given-names>R.</given-names></name>
<name><surname>Vukotic</surname><given-names>R.</given-names></name>
</person-group><article-title>Hepatitis C Virus Core Antigen (HCVAg): An affordable assay to monitor the efficacy of treatment in DAAs era</article-title><source>New Microbiol.</source><year>2021</year><volume>44</volume><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">34151994</pub-id>
</element-citation></ref><ref id="B98-viruses-16-01863"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mancebo Mart&#x000ed;nez</surname><given-names>A.</given-names></name>
<name><surname>N&#x000fa;&#x000f1;ez Serrano</surname><given-names>P.</given-names></name>
<name><surname>Fern&#x000e1;ndez de Ca&#x000f1;ete Camacho</surname><given-names>J.C.</given-names></name>
<name><surname>Moreno Planas</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Hepatitis C Virus Core Antigen as an Alternative to RNA in the Assessment of Response to Treatment with Direct-acting Oral Antivirals</article-title><source>Hepat. Mon.</source><year>2021</year><volume>21</volume><fpage>856</fpage><lpage>864</lpage><pub-id pub-id-type="doi">10.5812/hepatmon.118579</pub-id></element-citation></ref><ref id="B99-viruses-16-01863"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arboledas</surname><given-names>J.C.A.</given-names></name>
<name><surname>Guerrero</surname><given-names>I.P.</given-names></name>
<name><surname>Rodr&#x000ed;guez</surname><given-names>M.J.B.</given-names></name>
<name><surname>Martos</surname><given-names>E.T.</given-names></name>
<name><surname>P&#x000e9;rez</surname><given-names>A.B.</given-names></name>
<name><surname>Le&#x000f3;n</surname><given-names>C.C.</given-names></name>
<name><surname>S&#x000e1;nchez</surname><given-names>J.F.S.</given-names></name>
<name><surname>Prieto</surname><given-names>M.D.L.</given-names></name>
<name><surname>Porcuna</surname><given-names>N.C.</given-names></name>
<name><surname>Moch&#x000f3;n</surname><given-names>M.D.O.</given-names></name>
</person-group><article-title>Hepatitis C virus core antigen in the management of patients treated with new direct-acting antivirals</article-title><source>Diagn. Microbiol. Infect. Dis.</source><year>2017</year><volume>89</volume><fpage>29</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2017.06.006</pub-id><pub-id pub-id-type="pmid">28669680</pub-id>
</element-citation></ref><ref id="B100-viruses-16-01863"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chevaliez</surname><given-names>S.</given-names></name>
<name><surname>Feld</surname><given-names>J.</given-names></name>
<name><surname>Cheng</surname><given-names>K.</given-names></name>
<name><surname>Wedemeyer</surname><given-names>H.</given-names></name>
<name><surname>Sarrazin</surname><given-names>C.</given-names></name>
<name><surname>Maasoumy</surname><given-names>B.</given-names></name>
<name><surname>Herman</surname><given-names>C.</given-names></name>
<name><surname>Hackett</surname><given-names>J.</given-names></name>
<name><surname>Cohen</surname><given-names>D.</given-names></name>
<name><surname>Dawson</surname><given-names>G.</given-names></name>
</person-group><article-title>Clinical utility of HCV core antigen detection and quantification in the diagnosis and management of patients with chronic hepatitis C receiving an all-oral, interferon-free regimen</article-title><source>Antivir. Ther.</source><year>2018</year><volume>23</volume><fpage>211</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.3851/IMP3042</pub-id><pub-id pub-id-type="pmid">27115431</pub-id>
</element-citation></ref><ref id="B101-viruses-16-01863"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>van Tilborg</surname><given-names>M.</given-names></name>
<name><surname>Al Marzooqi</surname><given-names>S.H.</given-names></name>
<name><surname>Wong</surname><given-names>W.W.</given-names></name>
<name><surname>Maan</surname><given-names>R.</given-names></name>
<name><surname>Vermehren</surname><given-names>J.</given-names></name>
<name><surname>Maasoumy</surname><given-names>B.</given-names></name>
<name><surname>Mazzulli</surname><given-names>T.</given-names></name>
<name><surname>Bolotin</surname><given-names>S.</given-names></name>
<name><surname>Garber</surname><given-names>G.</given-names></name>
<name><surname>Guerra</surname><given-names>F.</given-names></name>
</person-group><article-title>HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: Retrospective screening and diagnostic cohort studies</article-title><source>Lancet Gastroenterol. Hepatol.</source><year>2018</year><volume>3</volume><fpage>856</fpage><lpage>864</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(18)30271-1</pub-id><pub-id pub-id-type="pmid">30274834</pub-id>
</element-citation></ref><ref id="B102-viruses-16-01863"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>&#x00141;ucejko</surname><given-names>M.</given-names></name>
<name><surname>Tomasiewicz</surname><given-names>K.</given-names></name>
<name><surname>Olczak</surname><given-names>A.</given-names></name>
<name><surname>Tudrujek-Zdunek</surname><given-names>M.</given-names></name>
<name><surname>Halota</surname><given-names>W.</given-names></name>
<name><surname>Jelski</surname><given-names>W.</given-names></name>
<name><surname>Donica</surname><given-names>H.</given-names></name>
<name><surname>Krintus</surname><given-names>M.</given-names></name>
<name><surname>Mroczko</surname><given-names>B.</given-names></name>
<name><surname>Flisiak</surname><given-names>R.</given-names></name>
</person-group><article-title>Hepatitis C virus core antigen as a possible alternative for evaluation of treatment effectiveness after treatment with direct-acting antivirals</article-title><source>Br. J. Biomed. Sci.</source><year>2019</year><volume>76</volume><fpage>190</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1080/09674845.2019.1654790</pub-id><pub-id pub-id-type="pmid">31401936</pub-id>
</element-citation></ref><ref id="B103-viruses-16-01863"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chayanupatkul</surname><given-names>M.</given-names></name>
<name><surname>Chittmittraprap</surname><given-names>S.</given-names></name>
<name><surname>Pratedrat</surname><given-names>P.</given-names></name>
<name><surname>Chuaypen</surname><given-names>N.</given-names></name>
<name><surname>Avihingsanon</surname><given-names>A.</given-names></name>
<name><surname>Tangkijvanich</surname><given-names>P.</given-names></name>
</person-group><article-title>Efficacy of elbasvir/grazoprevir therapy in HCV genotype-1 with or without HIV infection: Role of HCV core antigen monitoring and improvement of liver stiffness and steatosis</article-title><source>Antivir. Ther.</source><year>2020</year><volume>25</volume><fpage>305</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.3851/IMP3370</pub-id><pub-id pub-id-type="pmid">32910788</pub-id>
</element-citation></ref><ref id="B104-viruses-16-01863"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nouh</surname><given-names>M.A.E.-D.</given-names></name>
<name><surname>Elhelbawy</surname><given-names>M.G.</given-names></name>
<name><surname>Soliman</surname><given-names>M.A.B.M.</given-names></name>
<name><surname>El-Gazzarah</surname><given-names>A.R.</given-names></name>
</person-group><article-title>Cost-effectiveness of HCV core antigen versus PCR for monitoring treatment response in DAAS-treated Egyptian patients</article-title><source>Afro-Egypt. J. Infect. Endem. Dis.</source><year>2020</year><volume>10</volume><fpage>174</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.21608/aeji.2020.26287.1060</pub-id></element-citation></ref><ref id="B105-viruses-16-01863"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ko</surname><given-names>P.H.</given-names></name>
<name><surname>Tseng</surname><given-names>C.W.</given-names></name>
<name><surname>Tseng</surname><given-names>K.C.</given-names></name>
<name><surname>Chen</surname><given-names>Y.C.</given-names></name>
<name><surname>Hsu</surname><given-names>C.S.</given-names></name>
</person-group><article-title>The utility of HCV core antigen for evaluation of viremia at 48 weeks posttreatment with direct-acting antivirals</article-title><source>Adv. Dig. Med.</source><year>2023</year><volume>10</volume><fpage>80</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1002/aid2.13316</pub-id></element-citation></ref><ref id="B106-viruses-16-01863"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ananchuensook</surname><given-names>P.</given-names></name>
<name><surname>Wongpiyabovorn</surname><given-names>J.</given-names></name>
<name><surname>Avihingsanon</surname><given-names>A.</given-names></name>
<name><surname>Tangkijvanich</surname><given-names>P.</given-names></name>
</person-group><article-title>Performance of Elecsys<sup>&#x000ae;</sup> HCV Duo Immunoassay for Diagnosis and Assessment of Treatment Response in HCV Patients with or without HIV Infection</article-title><source>Diagnostics</source><year>2024</year><volume>14</volume><elocation-id>2179</elocation-id><pub-id pub-id-type="doi">10.3390/diagnostics14192179</pub-id><pub-id pub-id-type="pmid">39410582</pub-id>
</element-citation></ref><ref id="B107-viruses-16-01863"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kanokudom</surname><given-names>S.</given-names></name>
<name><surname>Poovorawan</surname><given-names>K.</given-names></name>
<name><surname>Nilyanimit</surname><given-names>P.</given-names></name>
<name><surname>Suntronwong</surname><given-names>N.</given-names></name>
<name><surname>Aeemjinda</surname><given-names>R.</given-names></name>
<name><surname>Honsawek</surname><given-names>S.</given-names></name>
<name><surname>Poovorawan</surname><given-names>Y.</given-names></name>
</person-group><article-title>Comparison of anti-HCV combined with HCVcAg (Elecsys<sup>&#x000ae;</sup> HCV Duo immunoassay) and anti-HCV rapid test followed by HCV RNA analysis using qRT-PCR to identify active infection for treatment</article-title><source>PLoS ONE</source><year>2024</year><volume>19</volume><elocation-id>e0313771</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0313771</pub-id><pub-id pub-id-type="pmid">39556526</pub-id>
</element-citation></ref><ref id="B108-viruses-16-01863"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hansoongnern</surname><given-names>P.</given-names></name>
<name><surname>Pratedrat</surname><given-names>P.</given-names></name>
<name><surname>Nilyanimit</surname><given-names>P.</given-names></name>
<name><surname>Wasitthankasem</surname><given-names>R.</given-names></name>
<name><surname>Posuwan</surname><given-names>N.</given-names></name>
<name><surname>Wanlapakorn</surname><given-names>N.</given-names></name>
<name><surname>Kodchakorn</surname><given-names>K.</given-names></name>
<name><surname>Kongtawelert</surname><given-names>P.</given-names></name>
<name><surname>Pimsing</surname><given-names>N.</given-names></name>
<name><surname>Poovorawan</surname><given-names>Y.</given-names></name>
</person-group><article-title>An amino acid substitution in HCV core antigen limits its use as a reliable measure of HCV infection compared with HCV RNA</article-title><source>PLoS ONE</source><year>2023</year><volume>18</volume><elocation-id>e0287694</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0287694</pub-id><pub-id pub-id-type="pmid">37384719</pub-id>
</element-citation></ref><ref id="B109-viruses-16-01863"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>J.H.</given-names></name>
<name><surname>Lee</surname><given-names>C.H.</given-names></name>
<name><surname>Lee</surname><given-names>S.W.</given-names></name>
</person-group><article-title>Hepatitis C virus infection stimulates transforming growth factor-&#x003b2;1 expression through up-regulating miR-192</article-title><source>J. Microbiol.</source><year>2016</year><volume>54</volume><fpage>520</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1007/s12275-016-6240-3</pub-id><pub-id pub-id-type="pmid">27350618</pub-id>
</element-citation></ref><ref id="B110-viruses-16-01863"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>J.H.</given-names></name>
<name><surname>Lee</surname><given-names>C.H.</given-names></name>
<name><surname>Lee</surname><given-names>S.-W.</given-names></name>
</person-group><article-title>Exosomal transmission of microRNA from HCV replicating cells stimulates transdifferentiation in hepatic stellate cells</article-title><source>Mol. Ther. Nucleic Acids</source><year>2019</year><volume>14</volume><fpage>483</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.1016/j.omtn.2019.01.006</pub-id><pub-id pub-id-type="pmid">30753992</pub-id>
</element-citation></ref><ref id="B111-viruses-16-01863"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shintani</surname><given-names>Y.</given-names></name>
<name><surname>Fujie</surname><given-names>H.</given-names></name>
<name><surname>Miyoshi</surname><given-names>H.</given-names></name>
<name><surname>Tsutsumi</surname><given-names>T.</given-names></name>
<name><surname>Tsukamoto</surname><given-names>K.</given-names></name>
<name><surname>Kimura</surname><given-names>S.</given-names></name>
<name><surname>Moriya</surname><given-names>K.</given-names></name>
<name><surname>Koike</surname><given-names>K.</given-names></name>
</person-group><article-title>Hepatitis C virus infection and diabetes: Direct involvement of the virus in the development of insulin resistance</article-title><source>Gastroenterology</source><year>2004</year><volume>126</volume><fpage>840</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2003.11.056</pub-id><pub-id pub-id-type="pmid">14988838</pub-id>
</element-citation></ref><ref id="B112-viruses-16-01863"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nakamoto</surname><given-names>S.</given-names></name>
<name><surname>Imazeki</surname><given-names>F.</given-names></name>
<name><surname>Fukai</surname><given-names>K.</given-names></name>
<name><surname>Fujiwara</surname><given-names>K.</given-names></name>
<name><surname>Arai</surname><given-names>M.</given-names></name>
<name><surname>Kanda</surname><given-names>T.</given-names></name>
<name><surname>Yonemitsu</surname><given-names>Y.</given-names></name>
<name><surname>Yokosuka</surname><given-names>O.</given-names></name>
</person-group><article-title>Association between mutations in the core region of hepatitis C virus genotype 1 and hepatocellular carcinoma development</article-title><source>J. Hepatol.</source><year>2010</year><volume>52</volume><fpage>72</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2009.10.001</pub-id><pub-id pub-id-type="pmid">19910070</pub-id>
</element-citation></ref><ref id="B113-viruses-16-01863"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sakata</surname><given-names>K.</given-names></name>
<name><surname>Hara</surname><given-names>M.</given-names></name>
<name><surname>Terada</surname><given-names>T.</given-names></name>
<name><surname>Watanabe</surname><given-names>N.</given-names></name>
<name><surname>Takaya</surname><given-names>D.</given-names></name>
<name><surname>Yaguchi</surname><given-names>S.-I.</given-names></name>
<name><surname>Matsumoto</surname><given-names>T.</given-names></name>
<name><surname>Matsuura</surname><given-names>T.</given-names></name>
<name><surname>Shirouzu</surname><given-names>M.</given-names></name>
<name><surname>Yokoyama</surname><given-names>S.</given-names></name>
</person-group><article-title>HCV NS3 protease enhances liver fibrosis via binding to and activating TGF-&#x003b2; type I receptor</article-title><source>Sci. Rep.</source><year>2013</year><volume>3</volume><elocation-id>3243</elocation-id><pub-id pub-id-type="doi">10.1038/srep03243</pub-id><pub-id pub-id-type="pmid">24263861</pub-id>
</element-citation></ref><ref id="B114-viruses-16-01863"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fuchs</surname><given-names>B.C.</given-names></name>
<name><surname>Hoshida</surname><given-names>Y.</given-names></name>
<name><surname>Fujii</surname><given-names>T.</given-names></name>
<name><surname>Wei</surname><given-names>L.</given-names></name>
<name><surname>Yamada</surname><given-names>S.</given-names></name>
<name><surname>Lauwers</surname><given-names>G.Y.</given-names></name>
<name><surname>McGinn</surname><given-names>C.M.</given-names></name>
<name><surname>DePeralta</surname><given-names>D.K.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Kuroda</surname><given-names>T.</given-names></name>
</person-group><article-title>Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma</article-title><source>Hepatology</source><year>2014</year><volume>59</volume><fpage>1577</fpage><lpage>1590</lpage><pub-id pub-id-type="doi">10.1002/hep.26898</pub-id><pub-id pub-id-type="pmid">24677197</pub-id>
</element-citation></ref><ref id="B115-viruses-16-01863"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khan</surname><given-names>S.</given-names></name>
<name><surname>Saxena</surname><given-names>R.</given-names></name>
</person-group><article-title>Regression of Hepatic Fibrosis and Evolution of Cirrhosis: A Concise Review</article-title><source>Adv. Anat. Pathol.</source><year>2021</year><volume>28</volume><fpage>408</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1097/PAP.0000000000000312</pub-id><pub-id pub-id-type="pmid">34326286</pub-id>
</element-citation></ref><ref id="B116-viruses-16-01863"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dharancy</surname><given-names>S.</given-names></name>
<name><surname>Malapel</surname><given-names>M.</given-names></name>
<name><surname>Perlemuter</surname><given-names>G.</given-names></name>
<name><surname>Roskams</surname><given-names>T.</given-names></name>
<name><surname>Cheng</surname><given-names>Y.</given-names></name>
<name><surname>Dubuquoy</surname><given-names>L.</given-names></name>
<name><surname>Podevin</surname><given-names>P.</given-names></name>
<name><surname>Conti</surname><given-names>F.</given-names></name>
<name><surname>Canva</surname><given-names>V.</given-names></name>
<name><surname>Philippe</surname><given-names>D.</given-names></name>
</person-group><article-title>Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection</article-title><source>Gastroenterology</source><year>2005</year><volume>128</volume><fpage>334</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2004.11.016</pub-id><pub-id pub-id-type="pmid">15685545</pub-id>
</element-citation></ref><ref id="B117-viruses-16-01863"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hassan</surname><given-names>M.</given-names></name>
<name><surname>Selimovic</surname><given-names>D.</given-names></name>
<name><surname>Ghozlan</surname><given-names>H.</given-names></name>
<name><surname>Abdel-Kader</surname><given-names>O.</given-names></name>
</person-group><article-title>Hepatitis C virus core protein triggers hepatic angiogenesis by a mechanism including multiple pathways</article-title><source>Hepatology</source><year>2009</year><volume>49</volume><fpage>1469</fpage><lpage>1482</lpage><pub-id pub-id-type="doi">10.1002/hep.22849</pub-id><pub-id pub-id-type="pmid">19235829</pub-id>
</element-citation></ref><ref id="B118-viruses-16-01863"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jahan</surname><given-names>S.</given-names></name>
<name><surname>Khaliq</surname><given-names>S.</given-names></name>
<name><surname>Ijaz</surname><given-names>B.</given-names></name>
<name><surname>Ahmad</surname><given-names>W.</given-names></name>
<name><surname>Hassan</surname><given-names>S.</given-names></name>
</person-group><article-title>Role of HCV Core gene of genotype 1a and 3a and host gene Cox-2 in HCV-induced pathogenesis</article-title><source>Virol. J.</source><year>2011</year><volume>8</volume><fpage>15</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-8-155</pub-id><pub-id pub-id-type="pmid">21232133</pub-id>
</element-citation></ref><ref id="B119-viruses-16-01863"><label>119.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><source>The Selection and Use of Essential In Vitro Diagnostics</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2021</year><isbn>978-92-4-001910-2</isbn></element-citation></ref><ref id="B120-viruses-16-01863"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cohn</surname><given-names>J.</given-names></name>
<name><surname>Roberts</surname><given-names>T.</given-names></name>
<name><surname>Amorosa</surname><given-names>V.</given-names></name>
<name><surname>Lemoine</surname><given-names>M.</given-names></name>
<name><surname>Hill</surname><given-names>A.</given-names></name>
</person-group><article-title>Simplified diagnostic monitoring for hepatitis C, in the new era of direct-acting antiviral treatment</article-title><source>Curr. Opin. HIV AIDS</source><year>2015</year><volume>10</volume><fpage>369</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1097/COH.0000000000000180</pub-id><pub-id pub-id-type="pmid">26185920</pub-id>
</element-citation></ref><ref id="B121-viruses-16-01863"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Kang</surname><given-names>Q.</given-names></name>
<name><surname>Luo</surname><given-names>H.</given-names></name>
<name><surname>Tan</surname><given-names>N.</given-names></name>
<name><surname>Pan</surname><given-names>J.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Yu</surname><given-names>M.</given-names></name>
<name><surname>Liu</surname><given-names>D.</given-names></name>
<name><surname>Xi</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Resistant-associated substitutions do not affect HCV RNA and HCV core antigen clearance during direct-acting antiviral agent treatment in a real-world setting</article-title><source>Infect. Drug Resist.</source><year>2022</year><volume>15</volume><fpage>3373</fpage><lpage>3380</lpage><pub-id pub-id-type="doi">10.2147/IDR.S352873</pub-id><pub-id pub-id-type="pmid">35789797</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-16-01863-f001"><label>Figure 1</label><caption><p>Structure of HCV. E: envelope glycoprotein; ssRNA: single-stranded RNA. Created with <uri xlink:href="https://www.biorender.com/">https://www.biorender.com/</uri> (accessed on 8 September 2024).</p></caption><graphic xlink:href="viruses-16-01863-g001" position="float"/></fig><fig position="float" id="viruses-16-01863-f002"><label>Figure 2</label><caption><p>Phylogenetic tree of the eight HCV genotypes based on genomes from the NCBI Genbank. Sequences were aligned using MEGA v.11 software, and the tree was constructed with the maximum likelihood method based on the GTR+G+I substitution model (automatically determined by the software). The nomenclature used is genotype-subtype-accession number. The graphical representation was generated using the iTOL website.</p></caption><graphic xlink:href="viruses-16-01863-g002" position="float"/></fig><fig position="float" id="viruses-16-01863-f003"><label>Figure 3</label><caption><p>Structure of HCV genome depicting the structural and functional map of an HCV core protein. Created with <uri xlink:href="https://www.biorender.com/">https://www.biorender.com/</uri> (accessed on 15 September 2024).</p></caption><graphic xlink:href="viruses-16-01863-g003" position="float"/></fig><fig position="float" id="viruses-16-01863-f004"><label>Figure 4</label><caption><p>The HCV life cycle. Adapted from [<xref rid="B17-viruses-16-01863" ref-type="bibr">17</xref>,<xref rid="B21-viruses-16-01863" ref-type="bibr">21</xref>]. Created with <uri xlink:href="https://www.biorender.com/">https://www.biorender.com/</uri> (accessed on 12 October 2024).</p></caption><graphic xlink:href="viruses-16-01863-g004" position="float"/></fig><fig position="float" id="viruses-16-01863-f005"><label>Figure 5</label><caption><p>Summary of the algorithm for HCV testing and treatment according to WHO 2022 and recommendations when resources are limited. Adapted from [<xref rid="B32-viruses-16-01863" ref-type="bibr">32</xref>,<xref rid="B36-viruses-16-01863" ref-type="bibr">36</xref>]. Created with <uri xlink:href="https://www.biorender.com/">https://www.biorender.com/</uri> (accessed on 15 October 2024).</p></caption><graphic xlink:href="viruses-16-01863-g005" position="float"/></fig><fig position="float" id="viruses-16-01863-f006"><label>Figure 6</label><caption><p>The sensitivity, specificity, and correlation between HCVcAg and HCV RNA in various studies.</p></caption><graphic xlink:href="viruses-16-01863-g006" position="float"/></fig><table-wrap position="float" id="viruses-16-01863-t001"><object-id pub-id-type="pii">viruses-16-01863-t001_Table 1</object-id><label>Table 1</label><caption><p>Comparison of Anti-HCV, HCVcAg, and HCV RNA Tests.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Characteristic</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Anti-HCV</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HCVcAg</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HCV RNA</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nature</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protein-Antibody</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protein-Antigen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nucleic acid</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Origin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCV-infected individual</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virus</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Time of appearance in blood after infection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8&#x02013;11 weeks after exposure</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Within 12&#x02013;15 days after exposure</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approximately 2 weeks after exposure</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Persistence in Blood</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virtually lifelong</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Disappears after successful treatment or clearance of HCV (usually within 6 months)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Disappears after successful treatment or clearance of HCV (usually within 6 months)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Testing principle</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Point-of-care: Lateral flow immunoassay<break/>Laboratory-based systems: Enzyme Immunoassay or Chemiluminescence Immunoassay Fluorescence immunoassays</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Point-of-care: Lateral flow immunoassay (Not commercially available)<break/>Laboratory-based systems: Enzyme Immunoassay or Chemiluminescence Immunoassay</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Point-of-care: Reverse transcription polymerase chain reaction.<break/>Laboratory-based systems: Reverse transcription polymerase chain reaction</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advantages</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCV exposure marker: Indicates past or current HCV contact.<break/>Persistent positivity: Remains positive even after successful HCV clearance.<break/>Accessible testing: Cost-effective, simple to administer, and easily implemented on a large scale.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cost-effective: Lower cost than HCV RNA testing.<break/>Simplified testing: Easier to perform and less labor-intensive.<break/>Flexible sample handling: No need for immediate testing after sample collection; can be detected in dried blood spots.<break/>Comparable information: Provides similar information to HCV RNA testing regarding active infection.<break/>Good correlation with the gold standard (HCV RNA).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Remains the gold standard for diagnosis and treatment monitoring according to guidelines from reputable associations and organizations.<break/>Both qualitative, quantitative, and rapid tests are accepted according to WHO guidelines.<break/>Can quantify viral load</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limitations</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No infection status differentiation: Does not distinguish between active infection and resolved infection.<break/>Low sensitivity in early infection (window period).<break/>Cannot quantify viral load.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Less sensitive than HCV RNA, chances of missed detection.<break/>May have false positives or false negatives in certain conditions.<break/>Laboratory-based tests require expensive automated systems.<break/>Rapid tests are not yet approved.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High cost per test.<break/>Requires advanced equipment systems.<break/>Requires highly skilled technical personnel.<break/>Difficult to implement widely in resource-limited areas.</td></tr></tbody></table></table-wrap><table-wrap position="float" id="viruses-16-01863-t003"><object-id pub-id-type="pii">viruses-16-01863-t003_Table 3</object-id><label>Table 3</label><caption><p>A comprehensive review of studies on the value of HCVcAg in treatment monitoring from 2016 to the present.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No.</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Author (Year) [Ref.]</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Country<break/>(Continent)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sample Size</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HCV Genotype</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Co-Infection</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sample Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HCVcAg Reagent</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Treatment Point</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Kappa/<break/>Concordant</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Correlation <break/>(<italic toggle="yes">p</italic>-Value)</th></tr></thead><tbody><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Nguyen et al. (2016) [<xref rid="B95-viruses-16-01863" ref-type="bibr">95</xref>]</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Ireland<break/>(Europe)</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">110</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">PM<break/>SR</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baseline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.882 <break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Week 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.743</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Week 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.678</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Week 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.505</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">42</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">PM<break/>SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baseline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.785</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Week 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.952</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alonso et al. (2017) [<xref rid="B69-viruses-16-01863" ref-type="bibr">69</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spain<break/>(Europe)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1, 2, 3, 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35.7% HIV<break/>28.6% HIV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EOT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.96</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.871</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">3</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Arboledas et al.<break/>(2017) [<xref rid="B99-viruses-16-01863" ref-type="bibr">99</xref>]</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Spain<break/>(Europe)</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">262</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1, 2, 3, 4</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">31.3% HIV</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">PM</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baseline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.396</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Week 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.175</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Week 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.225</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EOT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.386</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">4</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Loggi et al. (2017) [<xref rid="B96-viruses-16-01863" ref-type="bibr">96</xref>]</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Italy<break/>(Europe)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">96</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1, 2, 3, 4</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">36% HBV</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SR</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baseline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.767<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Overall</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.62</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">5</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Rockstroh et al. (2017) [<xref rid="B72-viruses-16-01863" ref-type="bibr">72</xref>]</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Germany<break/>(Europe)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">411</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">PM</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baseline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.5%</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.867<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PT Week 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.46%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PT Week 12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.75%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">France<break/>(Europe)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">631</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Architect HCVcAG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Overall</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.867<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">7</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Chevaliez et al. (2018) [<xref rid="B100-viruses-16-01863" ref-type="bibr">100</xref>]<break/>van Tilborg et al. (2018) [<xref rid="B101-viruses-16-01863" ref-type="bibr">101</xref>]</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Canada, Germany, and the USA<break/>(America and Europe)</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">219</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1, 2, 3, 4, 5,6</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.4% HBV</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SR</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baseline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.72<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Week 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.16<break/>(<italic toggle="yes">p</italic> = 0.04)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EOT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.93<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PT Week 12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.97<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PT Week 24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.97<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">8</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">&#x00141;ucejko et al. (2019) [<xref rid="B102-viruses-16-01863" ref-type="bibr">102</xref>]</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Poland<break/>(Europe)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">514</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">PM</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baseline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.1%,</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.75<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EOT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.9%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PT Week 12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.7%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">9</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Taiwan<break/>(Asia)</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">110</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">7%HBV</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SR</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baseline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.5%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.879<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Week 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36.6%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Week 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">47.7%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EOT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">84.1%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PT Week 12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">10</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Maneerat Chayanupatkul et al. (2020) [<xref rid="B103-viruses-16-01863" ref-type="bibr">103</xref>]</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Thailand<break/>(Asia)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">101</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">36.6% HIV</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SR</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baseline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.867<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SVR 12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.996<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SVR 24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.994<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nouh et al. (2020) [<xref rid="B104-viruses-16-01863" ref-type="bibr">104</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Egypt<break/>(Africa)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quick Titer&#x02122; (Glory Science) HCVcAG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baseline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.677<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">12</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Mancebo et al. (2021) [<xref rid="B98-viruses-16-01863" ref-type="bibr">98</xref>]</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Spain<break/>(Europe)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">274</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1, 2, 3, 4, 5</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">PM</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baseline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.832<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.01)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PT Week 12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.775<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.01)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">13</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Rossetti et al. (2021) [<xref rid="B97-viruses-16-01863" ref-type="bibr">97</xref>]</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Italy<break/>(Europe)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">180</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1, 2, 3, 4</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">PM<break/>SR</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baseline</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.8<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.01)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Overall</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.75<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.01)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">14</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Ko et al. (2022) [<xref rid="B105-viruses-16-01863" ref-type="bibr">105</xref>]</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Taiwan<break/>(Asia)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">98</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1, 2, 6</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">PM</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baseline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.951<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PT Week 12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PT Week 48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">15</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Vieira et al. (2023) [<xref rid="B91-viruses-16-01863" ref-type="bibr">91</xref>]</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Portugal<break/>(Europe)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">131</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SR</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.789</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EOT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.638</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SVR 12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">16</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Jaya Garg et al. (2024) [<xref rid="B93-viruses-16-01863" ref-type="bibr">93</xref>]</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">India<break/>(Asia)</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">90</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">N/A</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">PM</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Architect HCVcAG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baseline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.93<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PT Week 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.94<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)<break/></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PT Week 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.91<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PT Week 8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.82<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PT Week 12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.82<break/>(<italic toggle="yes">p</italic> &#x0003c; 0.0001)</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: EOT: end of treatment; HBV: hepatitis B virus; HCV: hepatitis C virus; HIV: human immunodeficiency virus; N/A: no data available; PM: plasma, SR: serum; USA: United States of America; Ref.: reference; PT: post-treatment; SVR: sustained virological response.</p></fn></table-wrap-foot></table-wrap></floats-group></article>